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In ovarian cancer, the standard of care treatment, which is surgery followed by 
chemotherapy, has remained relatively unchanged for over the last forty years. However, 
the overall survival rate for ovarian cancer has stagnated to only ~ 40%. This is due to long-
standing clinical challenges in the treatment of ovarian cancer including patients often 
having advanced stage disease at the time of diagnosis and majority of patients will exhibit 
recurrence and eventually acquire chemoresistant disease. Unfortunately, after patients no 
longer respond to chemotherapy, most will succumb to their disease due to the lack of 
efficacious alternative treatment modalities.  
The goal of this dissertation was to develop biomaterial-based approaches which can help 
improve ovarian cancer treatment. In Chapter 2, a biomaterial platform immobilizing 
ovarian cancer cells into stiff yet porous silica gels is described. The response to 
immobilization in stiff silica gels by ovarian cancer cells was extensively characterized, 
and it was shown that this platform can select for ovarian cancer cells with an enhanced 
ability to enter a non-proliferative state in order to tolerate the stress of physical 
confinement. Further, these cells could be removed from silica gels and were more resistant 
to platinum- and taxane-based chemotherapy, despite being proliferative at the time of drug 
treatment. It was also observed that silica gels could distinguish ovarian cancer cells with 
enhanced chemoresistance relative to more chemosensitive cells, as seen by enhanced 
survival upon immobilization. When compared to other in vitro platforms commonly used 
to induce quiescence, the silica gel immobilization platform could better select for ovarian 
cancer cells with enhanced chemoresistance. 
Chapter 3 discusses a facile method to incorporate iron oxide particles into microporous 
poly(caprolactone) (PCL) scaffolds previously developed in our group. These scaffolds 
have previously been shown to recruit metastatic breast cancer cells in vivo, and we sought 
to modify the scaffolds to be able to non-invasively kill cells after they arrived at this 
known targetable site. After successful incorporation of iron oxide into the scaffolds, it was 
demonstrated that they exhibited heating when placed under an alternating magnetic field 
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(AMF). Simple design parameters like the amount of iron oxide loaded into scaffolds or 
magnetic field strength could be tuned to alter the overall temperature rise exhibited by 
iron oxide-loaded scaffolds under AMF. The iron oxide itself did not cause cytotoxic 
effects, but iron oxide-loaded scaffolds under AMF could be used to successfully heat and 
kill loaded ovarian cancer cells in vitro. After implantation in the peritoneal cavity of 
female mice, iron oxide-loaded scaffolds became infiltrated with tissue after 6-7 weeks, 
and ex vivo AMF treatment of these iron oxide-loaded scaffolds could be used to kill 
infiltrated cells. Lastly, non-invasive hyperthermic treatment could be administered to mice 
with implanted iron oxide-loaded scaffolds, and iron oxide-loaded scaffolds under AMF 
could effectively kill infiltrated cells in vivo. 
Chapter 4 further explores the potential of the PCL-only and iron oxide-loaded scaffolds 
to be used as a therapy for ovarian cancer. The use of an advanced stage ID8 ovarian cancer 
mouse model is first described, since our group has not used this type of cancer model 
before. The mouse model exhibited hallmarks of advanced stage disease, including ascites 
accumulation and extensive metastases within the peritoneal cavity. Because the ID8 
ovarian cancer cells were not labeled, a method to quantify the extent of disease during 
disease progression and at study end-points was implemented. More importantly, the 
ability of the scaffolds to capture disseminated ovarian cancer cells in vivo was 
investigated. PCL-only scaffolds were able to capture disseminated ovarian cancer cells in 
vivo, regardless of whether they were implanted prior to cancer cell injection or during 
disease progression. Most notably, iron oxide-loaded scaffolds successfully captured 
disseminated ovarian cancer cells throughout disease progression, and significant disease 
formation was not necessary for cancer cell capture at iron oxide-loaded scaffolds. Lastly, 
future studies to expand upon the work described here are recommended in Chapter 5. 
Overall, the biomaterial-based approaches developed and discussed in this dissertation 
could be used to help improve the treatment of ovarian cancer. 
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Chapter 1: Introduction 
 
1.1 Ovarian cancer and standard of care treatment 
Ovarian cancer is the fifth-leading cause of cancer-related death in women, and ~ 22,000 
women in the U.S. will be diagnosed with ovarian cancer each year, with 64% of these 
patients ultimately succumbing to the disease1. In recent decades, improvements have been 
made to optimize the standard of care for ovarian cancer which includes surgery followed 
by platinum- and taxane-based chemotherapy. However, the overall cure rate for patients 
has stagnated to only around 40%2, leaving ovarian cancer as the most lethal gynecologic 
malignancy1. A significant obstacle in the treatment of ovarian cancer has been that most 
patients will have advanced stage disease, where the cancer has spread beyond the primary 
tumor, at the time of diagnosis. Advanced stage patients will often have metastases 
throughout the abdominal cavity and may have ascites - a protein-rich fluid associated with 
malignancy and poor prognosis - prior to even starting treatment. An additional long-
standing challenge has been that a significant number of patients will exhibit cancer 
recurrence after completing initial treatment and no longer respond to chemotherapy. 
Lastly, although it is well-known that many patients will stop responding to drug treatment, 
alternative therapies for ovarian cancer are sparse and have shown limited success. 
 
Ovarian cancer is a highly mutated cancer3, and it is often marked by multiple genetic and 
epigenetic abnormalities4. Many tumor suppressor genes and oncogenes have previously 
been implicated in ovarian cancer5. An oncogene is a mutated form of a gene typically 
involved in normal cell growth and drives cancer proliferation, while a tumor suppressor 
gene is one that regulates cell growth, but its mutation and loss of function can lead to 
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cancer. In a comprehensive analysis performed by The Cancer Genome Atlas in 20116, it 
was discovered that a number of genes were significantly mutated in ovarian cancers, and 
one of the most common abnormalities involved the mutation and loss of p53 gene 
function. The p53 gene is a tumor suppressor gene that is activated under various cellular 
stimuli or stress - most importantly DNA damage - which can lead to cell cycle arrest, 
senescence, and apoptosis. The most common outcome of all p53 mutations is loss of 
function7, resulting in loss of the original tumor suppression activity of the wildtype p53 
gene and its regulation of cell cycle arrest and apoptosis in DNA-damaged cells. Another 
genetic abnormality associated with ovarian cancer involves hereditary mutations in DNA 
repair genes, which comprises 10 - 15% of ovarian cancers8,9. The most well-known of 
these are mutations of the BRCA1 and BRCA2 genes. An essential way for cells to repair 
double-strand DNA breaks involves homologous recombination (HR) repair, and both 
BRCA1 and BRCA2 have multiple, unique roles in HR repair3. Consequently, patients with 
BRCA1/2 mutations will have an increased potential for cell oncogenesis compared to the 
general public3, with the lifetime risk of ovarian cancer increasing to 30 - 60% and 15 - 
30% for those with BRCA1 and BRCA2 mutations, respectively4. Here, a few well-known 
gene signatures in ovarian cancer are described, but extensive genomic profiling of ovarian 
cancer cell lines and patient samples has been completed10. Findings from Domcke et al. 
demonstrate the heterogeneity in both patients and commonly used ovarian cancer cell 
lines, and the authors challenge investigators to make informed decisions about which cell 
lines to use in studies (i.e. based upon genetic mutations, histological sub-type, site of 
origin) to increase clinical-relevance and the potential for developing promising therapies.  
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As indicated above, the histological sub-type and origin site of a patient’s tumor are 
important and can be indicative of prognosis and response to the standard of care treatment. 
The majority of ovarian cancers (80%) are of epithelial origin11, and epithelial ovarian 
cancers (EOCs) are further categorized into histological sub-types and grades. There are 
four main histological sub-types of epithelial ovarian cancer: serous, endometrioid, 
mucinous, and clear cell. Although they are all EOCs, each histological sub-type is known 
to differ in its genetic abnormalities, gene expression, disease biomarkers, and response to 
chemotherapy4. Notably, most EOCs are of the serous sub-type12, with 90% being 
specifically high-grade serous ovarian cancer (HGSOC)13. Because HGSOC is very 
aggressive and accounts for two-thirds of all ovarian cancer deaths14, it has been the most 
studied ovarian cancer sub-type. The site of origin of EOCs is also important, and there has 
been debate about whether EOCs originate from the ovarian surface epithelium (OSE) or 
the fallopian tube epithelium (FTE). First proposed by Fathalla in 1971, the “incessant 
ovulation” theory has been widely accepted, and it hypothesizes that the frequent ovulation 
cycle involving rupture and repair of the OSE may lead to its malignant transformation15. 
In recent decades, the FTE as a second site of origin has been noted, and studies have 
shown that the FTE near the ovary displays pre-neoplastic changes in women predisposed 
to ovarian cancer16,17. Overall, all the various genetic alterations and histo-pathologies have 
led to a broader classification of EOCs into Type I or Type II tumor sub-types for clinical 
treatment. Ovarian cancers classified as Type 1 are often slow growing, while Type II 




The heterogeneity in ovarian cancer tumors is also consequently reflected in the ovarian 
cancer cell lines used in preclinical studies. Using available genomic profiles from the 
Broad-Novartis Cancer Cell Line Encyclopedia19, Domcke et al. compared 47 ovarian 
cancer cell lines, including the most widely used SKOV-3, A2780, OVCAR-3, CAOV-3, 
and IGROV-1 cell lines10. It was discovered that mutated genes characteristic of HGSOC 
were also mutated in a significant fraction of the cell lines, with p53, BRCA1, and BRCA2 
mutated in 62%, 6%, and 9% of cancer cell lines, respectively. Specifically, the commonly 
used OVCAR-3 and CAOV-3 cell lines have p53 mutations and other gene abnormalities 
(i.e. high copy-number alterations) characteristic of HGSOC. Contrastingly, SKOV-3 and 
A2780 cell lines maintain wildtype p53 but carry mutations that are common in other 
histological sub-types. IGROV-1 was “hypermutated” relative to HGSOC and is predicted 
to not be HGSOC but instead an endometrial or clear cell ovarian cancer sub-type. The 
patients’ specimen type from which the cell lines were established and exposure to 
chemotherapy also differ. IGROV-1, CAOV-3, and A2780 were established from the 
primary tumor tissue of patients20, but OVCAR-3 and SKOV-3 originated from cells in 
patients’ ascites fluid21. The patient from which the A2780 cell line was established had 
not been treated with chemotherapy, and the IGROV-1 cell line is considered to be 
sensitive to cisplatin, the platinum-based drug of choice for ovarian cancer, which is 
consistent with the fact that the patient from which IGROV-1 was established had no prior 
chemotherapy treatment20. Contrastingly, the OVCAR-3 cell line was established from a 
patient who had progressive disease after combination chemotherapy - which included 
cisplatin - and is resistant to clinically-relevant doses of cisplatin21. Overall, the 
heterogeneity within patient tumors and ovarian cancer cell lines provides opportunity to 
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investigate and develop therapies tailored to specific ovarian cancer sub-types and groups 
of patients.  
Understanding how ovarian cancer metastasizes is also important for developing effective 
treatments, and ovarian cancer is unique from other cancers because of its route of 
metastasis. Other cancers which form solid primary tumors require disseminated cancer 
cells to undergo multiple intra- and extravasation steps through blood vasculature before 
arriving at sites permissive for metastasis, but in ovarian cancer, metastases are often 
confined within the peritoneal cavity after shedding from the primary tumor22. It is well 
accepted that the first step in ovarian cancer metastasis is for cells to undergo an epithelial-
to-mesenchymal (EMT) transition. In ovarian cancer, the EMT transition is mainly 
characterized by loss of E-cadherin expression, which results in decreased adherence and 
anchorage of neighboring epithelial cells23–25. Once cells have detached from the primary 
tumor, passive metastasis of disseminated cancer cells occurs through their transport in the 
peritoneal or ascites fluid either as single cells or as clusters of cells called spheroids. The 
disseminated ovarian cancer cells will often arrive at the peritoneum or omentum26 and use 
CD4427,28 and β-integrins29,30 to bind to the mesothelium lining. The peritoneum is the 
membrane that lines the abdominal cavity and organs, and the omentum is a structure of 
folds connected to the peritoneum made largely of fat, which connects the abdominal 
organs. The mesothelium lining consists of a single layer of cells attached to basement 
membrane that lines the abdominal cavity, including the peritoneum and omentum. After 
successful attachment, ovarian cancer cells will upregulate matrix metalloproteinase-2 
(MMP-2) to degrade extracellular matrix proteins to better adhere to the basement 
membrane. Lastly, it has been shown that these cells can promote blood vessel formation 
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to support secondary metastatic growth22, and angiogenesis through vascular endothelial 
growth factor (VEGF) has been shown to be important for the growth of intraperitoneal 
(i.p.) metastases and ascites production in vivo31.  
 
Currently, standard of care treatment for ovarian cancer involves debulking surgery 
followed by combination chemotherapy using platinum- and taxane-based agents. Because 
most patients are diagnosed at a stage where the cancer has spread, surgery aims to remove 
as much cancerous tissue as possible within the peritoneal cavity prior to chemotherapy. 
Ovarian cancer is one of the few cancers where surgery is routinely done but unlikely to 
remove all of the cancerous tissue, and studies have previously shown that more extensive 
surgeries (i.e. maximal cytoreductive surgery versus partial removal or biopsy only) help 
extend patient survival32–34. Single-agent chemotherapy of platinum-based agents was 
originally used in ovarian cancer treatment, and cisplatin has been the platinum-based drug 
of choice for over the last forty years, with patient prognosis correlating closely with 
response to cisplatin treatment35. Cytotoxic effects of cisplatin and other platinum-based 
drugs are mediated by formation of interstrand and intrastrand adducts between platinum 
and DNA36,37. These Pt-DNA adducts can disrupt the cell’s ability to properly replicate its 
DNA for cell division, and without effective DNA repair, the cell will undergo cell death 
by inducing apoptosis. Briefly, combination chemotherapy of cisplatin with 
cyclophosphamide was standard after surgery, as combination drug treatment provided 
synergistic effects relative to single-agent chemotherapy. However, following its 
introduction in the 1990s, paclitaxel - a taxane-based drug - combined with cisplatin in 
clinical trials demonstrated improved outcomes relative to cisplatin/cyclophosphamide and 
has been the standard of care since38,39. Taxane-based drugs promote apoptosis by 
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stabilizing the cell’s microtubules and does not allow their disassembly for chromosome 
separation during cell division which causes cell cycle arrest40. Interestingly, most ovarian 
cancer patients (70 - 80%) will have chemosensitive disease at diagnosis and respond to 
this current standard of care; however, even though most will initially respond to treatment, 
majority of patients will exhibit recurrence and ultimately succumb to the disease. 
 
1.2 Recurrence and chemoresistance 
Over 60% of ovarian cancer patients will eventually experience recurrence41. Currently, 
these patients have limited treatment options and are left with a more malignant form of 
the disease that is incurable with existing treatments42. Depending on their initial response 
to platinum-based chemotherapy, some ovarian cancer patients are re-treated with 
platinum-based chemotherapy. However, the probability of an effective secondary 
response to this treatment is low (Fig. 1.1)43, and it is predicted by the length of the patient’s 
previous response to platinum-based chemotherapy44. Unfortunately, it is recognized in the 
clinic that all patients with recurrent disease will eventually exhibit platinum-resistance42. 
Further, about 25% of patients will have platinum-resistant disease, which is defined by 
recurrence within 6 months of completing treatment42,43,45. For these ovarian cancer 
patients and ones who stop responding to secondary platinum-based chemotherapy, the 
standard practice is to next try treatment with another single-agent chemotherapy46,47. 
However, low response rates are typical47, and in phase II clinical trials, overall response 
rates have been shown to only range from 10 - 35% followed by disease progression after 
8 months48. Eventually, most patients will develop multi-drug resistance to whichever 
chemotherapeutics are used, suggesting the need to shift away from cytotoxic drugs 




Figure 1.1: Clinical classifications of platinum sensitivity and probability of secondary 
response to re-treatment with platinum-based chemotherapy43. 
 
Numerous strategies are being investigated for their utility in predicting patient response 
to chemotherapy. Patient-derived xenograft models have been explored for potential 
correlation between patient and avatar response to chemotherapy. Past studies have shown 
that mice bearing xenografts from patients responding poorly to platinum chemotherapy 
also experienced tumor progression during in vivo treatment, while mice responding well 
to treatment corresponded to patients with better progression-free survival (PFS)49,50. In 
vitro chemoresponse assays – such as the ATP-tumor chemosensitivity assay (ATP-TCA) 
and extreme drug resistance (EDR) assay – have also been investigated for the ability to 
identify resistance to individual drugs. The EDR assay testing platinum compounds has 
previously shown promise for predicting ovarian cancer patient overall response to 
platinum/taxane combination therapy and response to platinum-based treatment alone51. 
Additionally, clinical trials have shown that using ATP-TCA to guide decisions throughout 
multiple rounds of chemotherapy leads to improved survival for ovarian cancer patients52. 




be used in research trials and have not been recommended for use in clinical practice due 
to limitations of the studies that have been completed thus far51,53. Lastly, many studies 
have focused on whether gene expression of tumor cells from biopsy samples or cancer 
cell lines can be used to identify gene signatures or biomarkers for resistance to 
chemotherapy. Platforms involving microarrays, immunohistochemistry, and other 
methods are being investigated. However, a gene signature predicting clinical resistance 
has not yet been identified, and biomarkers associated with chemoresistance still require 
further validation before they would be used to inform clinical treatment decisions54,55.  
 
The main modes of chemoresistance in ovarian cancer are posited to be mechanisms 
involving increased DNA repair, enhanced drug efflux/detoxification, and increased 
tolerance of DNA damage leading to decreased apoptosis and pro-survival outcomes for 
cancer cells37. As platinum agents are the drug of choice in ovarian cancer, enhanced DNA 
repair mechanisms involving removal of Pt-DNA adducts are believed to be a primary 
source of chemoresistance in ovarian cancer. Enhanced use of the nucleotide excision 
repair (NER) pathway and specifically expression of ERCC-1, a key enzyme in the NER 
pathway, are known to correlate with clinical resistance to platinum-based chemotherapy56. 
ERCC-1 along with other NER components and innate DNA repair pathways are currently 
being investigated as predictive biomarkers for patient response to platinum chemotherapy. 
Enhanced expression of transport proteins such as multi-drug resistance protein 1 and P-
gp are also associated with chemoresistance, since they are known to decrease drug 
accumulation of multiple types of chemotherapy in ovarian cancer57. Glutathione and 
glutathione S transferases also aid in detoxification of various chemotherapeutic agents58, 
ultimately contributing to multi-drug resistance in ovarian cancer. Further, imbalance of 
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anti- and pro-apoptotic signaling can lead to the development and maintenance of 
chemoresistance in ovarian cancer, and pathways necessary for induction or inhibition of 
apoptosis (i.e. p53, Akt, PI3K) are typically dysregulated in ovarian cancer, which may 
ultimately contribute to survival of cancer cells during chemotherapy treatment59. 
 
1.3 Cellular dormancy and its potential role in ovarian cancer chemoresistance 
With many ovarian cancer patients initially responding to frontline treatments and some 
exhibiting complete remission prior to recurrence, it is posited that a potential cause of 
recurrence is the reawakening of dormant cancer cells that survive treatment60,61. Dormant 
cancer cells are not progressing through the cell cycle and actively dividing (Fig. 1.2), and 
instead, they exist in a reversible, non-proliferative state due to growth arrest in the G0/G1 
phase. Consequently, dormant cancer cells are characterized by loss of the Ki67 
proliferation-specific biomarker, as loss of Ki67 expression indicates exit from the cell 
cycle into a resting (G0) phase62. Dormant cancer cells may be present in a patient as early 
as development of the primary tumor or they can be left behind as minimal residual disease 
after what appears to be successful initial treatment63. Within a primary tumor, there is 
great heterogeneity in the cancer cell population, and while cancer cells are often 
characterized as rapidly dividing, a considerable proportion of these cancer cells will 
remain in a non-proliferative state61. Another source of dormant cancer cells are 
disseminated tumor cells shed from the primary tumor which can become dormant after 
arriving at sites not permissive to proliferation such as hypoxic and nutrient-deficient 
environments64. Furthermore, a cancer stem cell hypothesis has emerged suggesting that 
innately chemoresistant and dormant cancer cells with stem cell characteristics may reside 
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within the primary tumor, persist through chemotherapy, and repopulate chemoresistant 
disease after months or years upon completing treatment60.  
 
 
Figure 1.2: Schematic of the cell cycle. Cells in the G1, S, G2, and M phases are actively growing 
or dividing. Some cells may also undergo temporary growth arrest by exiting from the cell cycle 
into the G0 phase. 
 
Although cancer cell dormancy has been established to play a crucial role in cancer 
progression and recurrence, the mechanisms by which cancer cells enter dormancy remain 
poorly understood. Moreover, not all cancer cells are able to enter dormancy, and it is 
unclear why only a unique subset of these cells is able to undergo growth arrest to survive 
unfavorable conditions. Understanding the genetic mechanisms allowing cancer cells to 
transiently enter and reawaken from the dormant state could help minimize recurrence, but 
extensive study of cancer cell dormancy has been hindered due to the inability to easily 
collect these rare cells for study.  
 
Since most chemotherapy drugs kill rapidly dividing cells, it is believed that cancer cells 
which can readily enter dormancy have an enhanced ability to evade destruction during 
chemotherapy treatment and may ultimately engender chemoresistant disease. These 
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cancer cells may evade frontline chemotherapy treatment because they are innately drug-
resistant or have a propensity to become drug-resistant after entering a latent state due to 
adverse environments61. Therefore, it is probable that cancer cells which have entered 
dormancy and previously been exposed to chemotherapeutics, but were not destroyed, can 
reawaken and establish secondary, chemoresistant disease once favorable conditions are 
restored37,60. Similar findings have been discovered in other cancer types such as breast 
cancer, where residual tumor cells can maintain an asymptomatic, dormant state for months 
to years. These cells also appear to bear drug-resistant mechanisms protecting them from 
initial chemotherapy eventually resulting in disease recurrence63,64. 
 
While the precise link between chemoresistance and dormancy in ovarian cancer is 
unknown, it is suggested that these two cellular processes are related since ovarian cancer 
patients who recur will ultimately have incurable, chemoresistant disease42. Because 
platinum-mediated cytotoxicity is dependent on DNA damage recognition to induce 
apoptosis, dormancy-capable cancer cells are less likely to be affected by treatment since 
they can exit the cell cycle, at which point they will not attempt to replicate their DNA for 
cell division. Additionally, cancer cells that are less proliferative may have more time for 
drug detoxification or Pt-DNA adduct removal before Pt-DNA adducts are discovered by 
the necessary protein complexes that induce apoptosis. With taxane-based agents, the drug 
mechanism of action involves pushing cells into cell cycle arrest followed by apoptosis due 
to altered chromosome separation; however, this mechanism may not be as lethal for cells 
which readily enter dormancy/cell cycle arrest in order to tolerate stressful environmental 
conditions. Although recurrence and chemoresistance have remained common outcomes 
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for ovarian cancer patients, alternative treatment modalities that can minimize these events 
and are efficacious are limited. 
 
1.4 Alternative treatment options for ovarian cancer 
Anti-angiogenic agents, poly ADP ribose polymerase (PARP) inhibitors, and 
immunotherapies have been investigated as alternative treatments, but these approaches 
are far from replacing the current standard of care. Anti-angiogenic agents have been used 
to combat ovarian cancer because angiogenesis and angiogenic-related genes have proven 
to play a crucial role in ovarian tumor growth and disease progression through ascites 
formation and metastatic spread65,66. The most widely studied anti-angiogenic therapy for 
all tumor types and for EOCs has been an anti-VEGF monoclonal antibody, 
bevacizumab66, and 21% of recurrent ovarian cancer patients exhibited some response to 
treatment, with 40% exhibiting a PFS of at least 6 months in a phase II clinical trial67. 
However, most trials with anti-angiogenic agents have had difficulty demonstrating 
improvement in overall survival46, and despite the fact that almost all ovarian cancer 
patients will be treated with an anti-angiogenic agent, cure rates have remained stagnant66. 
PARP inhibitors, which prevent repair of single-strand DNA breaks, are intended to be 
used as a maintenance therapy or in combination with chemotherapy. Further, they are of 
interest for ovarian cancer patients with tumors harboring BRCA1/2 mutations or other 
defects in HR repair, and PARP inhibitors have most notably improved the PFS in these 
patient groups68. However, like chemotherapy, patients can develop resistance to PARP 
inhibitors, and this form of treatment would likely not be effective for patients who have 




Immunotherapy holds promise as an alternative treatment modality for ovarian cancer 
because of the potential for the patient’s immune system to develop memory against tumor-
specific antigens, which could help address recurrence. Thus far, two main strategies have 
been investigated in ovarian cancer clinical trials: immune checkpoint inhibitors (ICIs) and 
adoptive cell therapies (ACTs). ICIs aim to mitigate the immune system’s own regulation 
by using antibodies to block immune cell inhibitory receptors that induce 
immunosuppression, and this allows the immune cells to continue attacking cancer cells. 
Various antibodies targeting checkpoint receptors of PD-1, PD-L1, and CTLA-4 have been 
investigated in recurrent ovarian cancer patients, but they have shown limited success, with 
objective response rates only ranging from 6 - 15%69. ACTs involve ex vivo expansion and 
reinfusion of a patient’s own tumor-infiltrating lymphocytes (TILs) or re-engineered T 
cells with a chimeric antigen receptor to target and kill cancer cells. Although ACTs have 
shown great success in other types of cancer (i.e. melanoma70,71), ACTs have provided little 
improvement in EOCs69,72. Although ICIs and ACTs have shown minimal benefits on their 
own, combining them with previously used treatment modalities (i.e. chemotherapy, PARP 
inhibitors) or with other immunotherapies are worthwhile, and these combination 
treatments are currently under investigation. Immunotherapy clinical trial results have 
overall remained mixed with immunologic responses varying from patient to patient, 
making treatment strategies difficult to standardize73,74. Mixed responses to 
immunotherapy likely stem from the differences in immune cell populations within the 
patient’s tumor microenvironment, and increased presence of TILs has been correlated 
with better survival in ovarian cancer, while patients with more immunosuppressive 
regulatory T cells typically have poorer outcome69. 
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Because most ovarian cancer patients are diagnosed at an advanced stage where the cancer 
is in a disseminated form, new alternative treatment options are limited to strategies that 
do not require localized disease. Consequently, promising treatment modalities such as 
focal therapies that can effectively kill all types of cancer cells at a targeted site cannot be 
used. For ovarian cancer, focal therapies could help address the challenges of recurrence 
and chemoresistance, as these modalities use energy-based processes – cryoablation, 
hyperthermia, or irreversible electroporation – to lyse cells. Being unbiased, focal therapies 
can be used to destroy dormancy-capable or chemoresistant cancer cells, unlike 
chemotherapy. Overall, a method to localize disseminated ovarian cancer cells to a specific 
site for treatment would allow study of focal therapies and other promising treatments that 
currently cannot be used. A potential strategy to capture disseminated ovarian cancer cells 
may involve polymer scaffolds, since they have previously been shown to localize disease 
in an advanced stage ovarian cancer model after implantation into the peritoneal cavity of 
mice75. Further, our group has developed microporous polymer scaffolds that can recruit 
metastatic breast cancer cells76,77, and their ability to capture disseminated cancer cells in 
ovarian cancer will be described here. Overall, innovative treatment modalities for ovarian 
cancer are needed as the existing standard of care – surgery and platinum- and taxane-
based chemotherapy – will often result in recurrence and chemoresistance. 
 
1.5 Biomaterial applications in cancer 
Biomaterials have emerged as useful tools in cancer research, and over the years, they have 
been widely used for study in in vitro tumor models, diagnostics, imaging, and drug 
delivery78. These biomaterials are made of materials naturally occurring in the body or 
tumor microenvironment, such as collagen and fibrin, or are synthetic systems derived 
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from materials which are not readily found in vivo such as silica-based materials or other 
synthetic polymers. For ovarian cancer, biomaterials involved in dormancy and 
chemoresistance research and applications to mitigate metastatic disease are of particular 
interest. Biomaterial matrices and scaffolds have been extensively used to model in vitro 
tumor microenvironments and to investigate which tunable material properties (i.e. 
composition, stiffness, architecture, chemical and biophysical factors) may result in 
dormancy or chemoresistance79–82. Further, biomaterial scaffolds loaded with cobalt 
chloride as a hypoxia-mimetic were shown to be useful as a potential platform to study 
dormancy in vivo83.  In addition to mechanistic studies of dormancy and chemoresistance, 
biomaterials have been explored for their potential as therapeutic tools to combat platinum-
resistance in ovarian cancer, either by enhancing delivery of chemotherapeutics or by 
delivering biological factors to re-sensitize cancer cells to platinum-based chemotherapy84. 
Biomaterials that can localize disseminated disease are also of interest since ovarian cancer 
is often diagnosed at an advanced stage. As mentioned above, polymer-based scaffolds 
have been used to recruit disseminated cancer cells in vivo in ovarian and breast cancer 
models75–77,85. Numerous studies have also used biomaterials to create a bone-mimicking 
niche to recruit breast, melanoma, and prostate cancer cells86–89. The rationale for these 
systems is that they mimic pre-metastatic niches or tissues/organs that are typical sites of 
metastasis76,77,87,90–92. Overall, biomaterials and their properties such as size, morphology, 
and composition can be easily tailored, which provides ample opportunity for their use as 
innovative research and therapeutic tools. They have proven useful in improving 
mechanistic understanding of disease through improved in vitro and in vivo tumor models 
to study clinical challenges such as dormancy and chemoresistance. Lastly, biomaterial 
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systems offer advantages over traditional delivery systems by allowing for targeted 
therapies to potentially improve treatment efficacy and lower adverse side effects.  
 
1.6 Scope and organization of thesis 
The scope of this thesis involves developing biomaterial-based approaches to address the 
clinical challenges in ovarian cancer treatment: chemoresistance, recurrence, and lack of 
alternative treatment modalities. In Chapter 2, an immobilization platform using stiff silica 
gels to select for chemoresistant ovarian cancer cells with an enhanced ability to enter 
dormancy is described. Chapter 3 discusses incorporation of iron oxide into our previously 
developed poly(caprolactone) (PCL) polymer scaffolds for heating and killing of infiltrated 
cells when placed under an alternating magnetic field. The work in Chapter 4 focuses on 
the potential of PCL-only and iron oxide-loaded scaffolds described in Chapter 3 to capture 
disseminated ovarian cancer cells in vivo in an advanced stage ovarian cancer mouse 
model. Lastly, Chapter 5 discusses future directions for these projects based upon the 









Chapter 2: Immobilization rapidly selects for chemoresistant 
ovarian cancer cells with enhanced ability to enter dormancy  
 
Adapted with permission from “T. Lam, J. A. Aguirre-Ghiso, M. A. Geller, A. Aksan, and 
S. M. Azarin; Immobilization rapidly selects for chemoresistant ovarian cancer cells with 
enhanced ability to enter dormancy, Biotechnology and Bioengineering, (2020) DOI: 
10.1002/bit.27479” Copyright 2020 John Wiley & Sons, Inc. 
 
2.1 Introduction 
As described in Chapter 1, significant challenges in ovarian cancer treatment are the fact 
that a subset of patients will have chemoresistant disease and that most patients will 
experience recurrence after completing chemotherapy treatment. Unfortunately, there is 
currently no rapid way to predict how responsive ovarian cancer patients will be to 
chemotherapy prior to treatment, as patient-derived xenograft (PDX) avatar models take 
months to establish93. Recently, 3-D in vitro models using patient tumor cells have shown 
promise as platforms for predicting patient drug response and require less time than PDX 
models94,95; however, even these methods can take weeks. The ability to rapidly identify 
patients (within days) who would not respond to chemotherapy would enable clinicians to 
adjust monitoring strategies or suggest alternative therapies that are often only used once 
conventional treatment no longer works.  
 
With many women initially responding to frontline treatments and some exhibiting 
complete remission, it is posited that recurrence and chemoresistance may be due to the 
presence of quiescent tumor cells that survive treatment60,61. Although cancer cells which 
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enter quiescence are known to evade chemotherapy and cause recurrence61, the 
mechanisms by which they survive drug treatment remain unclear, and further study is 
required to determine which mechanisms contribute to resistance in cells which readily 
undergo growth arrest in stressful conditions. However, study of these cells and their drug-
resistance mechanisms has been limited by the lack of suitable in vitro methods available 
to easily identify and isolate them.  
 
As entering dormancy is a mechanism for cells to survive in a microenvironment that is 
not conducive to growth, most in vitro platforms utilize environmental stress to induce 
quiescence. Oxygen-deficient or low-serum/low-glucose treatment methods are often used 
to mimic hypoxic and nutrient-deficient conditions in the body, and previous studies have 
demonstrated accumulation of growth-arrested cells in various tumor cell lines grown 
under these conditions96,97. Recent work has shown that the stress of physical confinement 
upon immobilization in stiff yet porous alkoxide-based silica gels results in the ability to 
distinguish between cells that are readily able to enter dormancy and those that cannot, as 
breast cancer cell lines known to readily form tumors in vivo quickly die upon physical 
confinement while another cell line known to enter quiescence in vivo demonstrates 
enhanced survival in a growth-arrested state98. As the quiescence-inducing stress in this 
model is matrix-based and interactions with the extracellular matrix (ECM) are also 
implicated in the responsiveness of ovarian cancer cells to chemotherapy60, we sought to 
investigate whether the stress of physical confinement and the silica gel environment 
potentiate chemoresistance, in addition to quiescence, in ovarian cancer.  
 
In this chapter, we report the use of physical confinement in silica gels to identify ovarian 
cancer cells which exhibit quiescence when immobilized and resume proliferation upon 
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extraction from the gel. This process selects for a population with a higher propensity to 
enter dormancy, as the extracted cells exhibit enhanced survival in the quiescent state upon 
re-immobilization. Interestingly, these extracted cells also demonstrate signaling responses 
similar to cells that have persisted following chemotherapy treatment, and accordingly the 
extracted cells are shown to be less sensitive to cisplatin and paclitaxel treatment than the 
original cell population. Furthermore, chemoresistant cells exhibit enhanced survival upon 
immobilization in the gels, indicating that they are more readily able to enter the dormant 
state. These findings demonstrate a linkage between chemoresistant and dormancy-capable 
phenotypes in ovarian cancer. As immobilization in silica gels can isolate populations with 
these phenotypes within days, this platform could be useful in future mechanistic or drug 
studies and could potentially be used as a tool to identify patients that may have 
chemoresistant disease and are at risk of recurrence. 
 
2.2 Materials and Methods 
2.2.1 Cell culture  
OVCAR-3 and SKOV-3 cells were purchased from the ATCC (HTB-161 and HTB-77). 
OVCAR-3 and SKOV-3 cells were cultured in RPMI 1640 media (Thermo Fisher 
Scientific) and McCoy's 5A media (Thermo Fisher Scientific), respectively, supplemented 
with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific). Cells were passaged when 
80 – 90% confluence was reached. OVCAR-3 was chosen as the primary cell line since it 
was established from a patient who maintained progressive disease after completing 
combination chemotherapy and is resistant to clinically-relevant doses of cisplatin and 




2.2.2 Immobilization of cells by silica gel encapsulation 
Silica gel matrices were formed from tetrakis(2-hydroxyethyl) orthosilicate (THEOS) and 
silica nanoparticles (SNPs) as described previously (Fig. 2.1A)98. Primary gelling solution 
consisted of FBS-supplemented cell culture media with 1% v/v penicillin-streptomycin 
(Thermo Fisher Scientific), 4-arm PEG (2 kDa, hydroxyl terminated, Creative PEGWorks), 
and NS125 silica nanoparticles (Nyacol) in a 0.9:0.1:0.02 volume ratio. Cells for 
encapsulation were trypsinized and cell solution at 2 × 106 cells per mL was added 1:1 with 
gelling solution and aliquoted to 50 µL per gel. Tetrakis (2-hydroxyethyl) orthosilicate 
(Gelest) was added to each aliquot at a 1:10 ratio and thoroughly mixed. Silica gel solution 
was quickly pipetted and spread onto a non-treated 35 mm polystyrene petri dish. Dishes 
were left untouched for a few minutes to allow complete gelling, after which media was 
added on top to prevent dehydration before incubating at 37 °C. OVCAR-3 cells were 
easily visualized within gels and observed to be intact and distributed primarily as single 





Figure 2.1: Silica gels formed from tetrakis(2-hydroxyethyl) orthosilicate (THEOS) and silica 
nanoparticles (SNPs) were used to immobilize OVCAR-3 cells. (A) Schematic of chemical 
formation of silica matrices by incorporating water with a silicon alkoxide, where addition of water 
causes hydrolysis of THEOS followed by condensation reactions producing ethylene glycol as a 
by-product. SNPs aid in gel network formation by acting as additional nucleation sites during 
gelation. (B) Phase-contrast image of cells (white arrows) after immobilization within a silica gel. 
Scale bar indicates 200 µm. 
 
2.2.3 Quantification of immobilized viable cells 
Immobilized cells were stained with Calcein AM (Thermo Fisher Scientific) diluted 1:500 
in phosphate buffered saline (PBS) for 30 minutes on a shaker platform at room 
temperature. Live cells were imaged using an EVOS FL Auto fluorescence microscope 
(Thermo Fisher Scientific) at 10x magnification. Ten images were taken for each timepoint 
(five images each from two separate gels), and the number of live cells was manually 
counted from each image. Fold change in viable cell number for each day was quantified 
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as total number of live cells counted in each gel normalized to average total number of live 
cells counted in gels on Day 0.  
 
2.2.4 Ki67 immunofluorescence analysis 
Washing was completed with PBS, and all incubation steps were at room temperature on a 
shaker platform. 2-D or silica gel samples were washed and then fixed with a 4% 
paraformaldehyde (PFA) solution for 12 or 20 minutes, respectively. Samples were washed 
again and incubated for 1 hour with blocking solution containing PBS with 5% normal goat 
serum (Thermo Fisher Scientific) and 0.3% Triton X-100 (Millipore Sigma). Ki67 primary 
antibody in antibody dilution buffer (PBS with 0.3% Triton x-100 and 1% bovine serum 
albumin (BSA) (Millipore Sigma)) was added to samples for overnight incubation at 4 °C. 
Samples were washed followed by addition of secondary antibody in antibody dilution 
buffer and incubated for 1 or 2 hours for 2-D or silica gel samples, respectively. All samples 
were washed before addition of 300 nM DAPI nuclear staining solution (Thermo Fisher 
Scientific) for 5 or 30 minutes for 2-D samples or silica gels, respectively. Samples were 
washed once more then imaged using an EVOS FL Auto fluorescence microscope with the 










Table 2.1: Detailed information for antibodies used in immunofluorescence (IF) and Western 




2.2.5 Senescence-associated β-galactosidase staining 
Staining was completed using the Senescence β-Galactosidase Staining Kit #9860 from 
Cell Signaling Technologies according to the manufacturer’s instructions. Briefly, 2-D or 
silica gel samples were washed then fixed with 1x fixative solution for 12 or 20 minutes, 
respectively. Samples were washed again, and β-galactosidase staining solution was 
prepared, adjusted to a final pH between 5.9 and 6.1, and added. Samples were covered 
with parafilm to prevent evaporation, and 2-D or silica gel samples were placed in a dry 37 
°C incubator overnight or for 24 hours, respectively. Brightfield images at 20x 
magnification were taken using an EVOS FL Auto fluorescence microscope. High passage 
human foreskin fibroblasts (ATCC; SCRC-1041) were used as a positive control.  
 
2.2.6 Cell extraction 
Gels were rinsed with PBS followed by incubation with 0.25% trypsin-EDTA for 7 minutes 
at 37 °C. Cells were then extracted from silica gels by pipetting with cell culture media to 
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break apart the gels. The gel fragment and media solution was transferred to a conical tube 
and further pipetted to break up large fragments. This solution was transferred to a T75 
flask containing cell culture media with 1% v/v penicillin-streptomycin and incubated 
overnight. Flasks were then washed two times with PBS to remove any remaining silica 
gel fragments, and fresh cell culture media with 1% v/v penicillin-streptomycin was added. 
For studies involving regrowth and treatment of extracted cells, extracted cells were 
imaged at the same locations (n ≥ 9 for each condition) for up to one week. Viable cell 
number was determined by manually counting cells from these images.  
 
2.2.7 Western blotting 
Protein was extracted from cells immobilized in silica gels for three days and cells 
maintained in standard 2-D culture using Halt Phosphatase Inhibitor Cocktail (Thermo 
Fisher Scientific) and Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific), each 
diluted 1:100 in RIPA lysis buffer (Thermo Fisher Scientific). For protein separation, 10 
µg of protein was loaded per well of a 4-15% Mini-Protean SDS-PAGE gel (Bio-Rad) for 
β-actin detection, and 30 µg of protein was loaded per well for detection of mitogen-
activated protein kinase (MAPK) proteins. Proteins were then transferred to a 
polyvinylidene difluoride membrane (Bio-Rad), and membranes for MAPK proteins and 
β-actin were blocked in Tris-buffered saline containing Tween-20 (TBS-T, Millipore 
Sigma) with 5% BSA or 5% non-fat dry milk (Bio-Rad), respectively, for 1 hour at room 
temperature. Membranes were then incubated overnight at 4 °C with primary antibodies in 
TBS-T with 5% BSA or 5% milk for MAPKs and β-actin, respectively. MAPK membranes 
were then rinsed and incubated with secondary antibody diluted in TBS-T with 5% BSA 
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for 1 hour at room temperature. SuperSignal West Pico Chemiluminescent substrate 
(Thermo Fisher Scientific) was used to detect protein bands, which were then imaged with 
a ChemiDoc Touch Imaging System (Bio-Rad). Western blot data was quantified using 
Image Lab software (Bio-Rad). The ratio of activated p38 is defined as the phosphorylated 
p38 MAPK “pp38” band intensity divided by the p38 MAPK “p38” band intensity. 
Similarly, the ratio of activated ERK is defined as the phosphorylated ERK1/2 MAPKs 
“pERK1/2” band intensity divided by the ERK1/2 MAPKs “ERK1/2” band intensity. The 
final p38:ERK activity ratio was then found by dividing these two ratios (ratio of activated 
p38/ratio of activated ERK). See supplemental information for antibody details (Table 
2.1). 
 
2.2.8 RNA-sequencing sample preparation and analysis 
Total RNA was collected from cells using the RNeasy Mini Kit (Qiagen) with two replicate 
samples collected for each condition (5 conditions, 10 samples total). 5 µg of RNA for each 
sample was submitted to the University of Minnesota Genomics Core for library creation 
and sequencing. Ten dual-indexed Illumina TruSeq stranded mRNA libraries were created 
for paired-end sequencing, and sequencing was completed in one lane of a HiSeq 2500 
2x125-bp run using v4 chemistry, providing a total of ~22 million reads per sample. 
Trimming of low-quality ends and removal of adapter sequences was completed using 
Trimmomatic. Spliced Transcripts Alignment to a Reference (STAR) was used for 
mapping of reads to the human reference genome (GRCh38.91). The HTseq package in 
Python was used to obtain raw counts per million for each gene, then the EdgeR package 
in R was used to determine the fold change and significance of gene expression in pair-
wise comparisons of the various experimental conditions relative to the control. Further 
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analyses of these genes included Gene Ontology enrichment analysis using Database for 
Annotation, Visualization, and Integrated Discovery (DAVID v6.8, 
https://david.ncifcrf.gov/) for genes meeting criteria of fold change ≥ 2 and P-value < 0.05 
and Ingenuity Pathway Analysis (IPA) (Qiagen) for genes with fold change ≥ 2, P-value < 
0.05, and false discovery rate < 0.05. For comparison to patient data, genes identified as 
differentially expressed between chemoresistant and chemosensitive patients in the 
discovery group by Koti et al. and in their in silico analysis of patient datasets from The 
Cancer Genome Atlas were used99. Differentially expressed genes from these analyses 
were compared to the differentially expressed genes in our “Extracted” group relative to 
control, and genes which were commonly up- or downregulated in both datasets were used 
in IPA to identify which canonical signaling pathways were most relevant to the common 
differential gene expression observed in the patient cohorts and our in vitro groups. 
 
2.2.9 Hypoxia, serum starvation, and drug treatment 
Cells were seeded with 10% FBS-supplemented cell culture media and after 24 hours, 
plates were then placed into a hypoxia chamber (STEMCELL Technologies) maintaining 
1% oxygen conditions for hypoxia treatment or media was aspirated and serum-free cell 
culture media was added to wells for serum starvation. For drug treatment studies, cells 
were seeded with 10% FBS-supplemented cell culture media and incubated at 37 °C 
overnight, and drug-containing media was freshly prepared prior to addition to cells for 
each treatment. Cells were grown in drug-containing media for 24 hours after each 
addition, then drug-containing media was aspirated and cells were rinsed with PBS 
followed by addition of fresh 10% FBS-supplemented cell culture media. Cisplatin 
(Millipore Sigma) was solubilized in ultrapure water by gentle stirring at 25 °C for 10-15 
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minutes then filtered and stored in the dark at room temperature as a 10 mM stock solution. 
Paclitaxel (Tocris) was reconstituted to a 100 mM stock solution with dimethyl sulfoxide, 
aliquoted, and stored at -20 °C. 
 
2.2.10 Hypoxia or serum starvation studies with cisplatin treatment 
Cells for standard culture, hypoxic, and serum starvation conditions were seeded at 
100,000, 250,000, or 500,000 cells per well, respectively, on 6 well-plates in 10% FBS-
supplemented cell culture media and incubated at 37 °C. Different seeding densities were 
chosen to ensure that the cell density for each condition was roughly the same at the start 
of cisplatin treatment. After 24 hours, cells were placed into a 1% oxygen hypoxia chamber 
or serum-free cell culture media was added to wells. After three days, media containing 0.5 
µM cisplatin was added to wells, while control wells received drug-free media. After 24 
hours of drug treatment, all wells were washed with PBS and fresh drug-free cell culture 
media was added. After three days, cells were stained with Trypan Blue (Thermo Fisher 
Scientific) and counted (Countess II Automated Cell Counter, Thermo Fisher Scientific). 
 
2.2.11 Statistical analysis 
Data are represented as mean ± S.D. of two or more biological replicates from one of three 
representative independent experiments or as mean ± S.D. from three combined 
independent experiments. P-values were determined from Student’s unpaired t-test using 







2.3 Results and Discussion 
 
2.3.1 Immobilized OVCAR-3 cells within silica gels exhibit hallmarks of single cell 
dormancy  
After immobilization in stiff yet porous silica gels which have previously been 
characterized and shown to inhibit cell motility, growth, and proliferation100, a substantial 
decrease in viable OVCAR-3 cells was observed over time, with surviving cells remaining 
in a single-cell state and having no evident increase in size (Fig. 2.2A). The percentage of 
Ki67-positive cells significantly decreased by Day 3 of immobilization and continued to 
decrease at later timepoints (Fig. 2.2B & Fig. 2.3), which was consistent with our previous 
observations with the MCF-7 breast cancer cell line98.  Ki67 is expressed in actively 
dividing cells and has been extensively characterized as a proliferation-specific marker, 
with loss of Ki67 expression indicating cell cycle exit into a resting (G0) phase62,101. 
Immobilized live cells also demonstrated an increased p38:ERK activity ratio and higher 
expression of phosphorylated p38 MAPK (Fig. 2.2C). A high p38:ERK activity ratio is an 
indicator for cancer cell transition from metastatic growth to quiescence64,102. Increased 
activation of p38 signaling is associated with response to environmental stress103 and tumor 
suppression104,105. Decreased ERK activity has been associated with small tumor nodules, 
while rapidly growing tumors and metastases exhibited high ERK activity in vivo106. 
Further, ERK and p38 levels have previously been shown to predict dormancy in vivo in 
epidermoid carcinoma, fibrosarcoma, and other tumor types, and inhibition of p38 activity 
has even reversed dormant behavior107,108. Importantly, growth-arrested cells in silica gels 
were not senescent, as senescence-associated β-galactosidase expression levels did not 
change during immobilization (Fig. 2.4). When extracted from the silica gels after three 
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days of immobilization, the cells resumed proliferation, exhibiting no significant 
differences in growth or morphology immediately after extraction compared to control 
cells (Fig. 2.2D & Fig. 2.5).  
 
RNA sequencing analysis revealed 1,426 and 1,031 differentially expressed genes after 24 
hours (“Day 1”) or 3 days (“Day 3”) of immobilization, respectively, relative to 2-D control 
cells, with 649 common differentially expressed genes between these groups (Fig. 2.2E). 
Gene Ontology (GO) enrichment analysis was next completed using differentially 
expressed genes (Fig. 2.2F&G). For significantly upregulated genes, terms related to stress 
and stimuli responses, along with interferon signaling, were enriched in both “Day 1” and 
“Day 3”, but apoptosis-related terms appeared only in “Day 1”. This result is unsurprising 
since the most significant reduction in viable cells occurs within the first two days of 
immobilization (Fig. 2.2A), and activation of apoptotic pathways would be present in many 
of these cells. Previous studies have also shown addition of exogenous interferon (IFN) 
induces cell cycle arrest in gastric109 and renal110 carcinoma cells. Wall et al. showed IFN-
gamma had an anti-proliferative effect on ovarian cancer cell lines in vitro, and they 
observed IFN treatment of platinum-refractory ovarian cancer patients caused significant 
cancer cell reduction although 2% residual disease remained, eventually leading to 
recurrence111. GO analysis of downregulated genes resulted in terms related to cell 
adhesion, cell-protein interactions, and metabolism in both groups. Terms such as ECM-
receptor interaction, integrin binding, and cell-substrate adhesion largely indicate a 
mechanotransduction signaling response of immobilized cells within silica gels, as cellular 
mechanotransduction is mediated by integrins and focal adhesions due to cell receptor 
binding and activation to various proteins of the extracellular matrix112,113. Reduced 
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metabolism96 and downregulation of PI3K-Akt signaling114–116 are associated with 
quiescence. Previous work has shown that malignant cells resisting anchorage-dependent 
apoptosis also have inactivated PI3K-Akt signaling and increased entrance into the G0 
phase117. Additionally, patient ovarian cancer cells and OVCAR-3 cells entered quiescence 
and had decreased AKT phosphorylation in non-adherent culture conditions115. These 
findings demonstrate the ability of silica gels to select for viable cells exhibiting dormant 






Figure 2.2: Immobilization of OVCAR-3 cells in silica gels results in survival of cells 
exhibiting quiescence. (A) Fluorescence images of viable cells stained with calcein AM (green) at 
Days 0, 1, 2, 3, 5, and 7 of immobilization.  Scale bar indicates 400 µm. (B) Percentage of Ki67-
positive cells (number of Ki67-expressing cells normalized to number of DAPI-labeled cells) 
within silica gels over a one-week period quantified from fluorescence images (*P < 0.05 compared 
to previous timepoint). (C) Western blotting of p38 MAPK protein (“p38”), ERK1/2 MAPK 
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proteins (“ERK1/2”), and their phosphorylated forms (“pp38” and “pERK1/2”) in cells 
immobilized for three days and control cells grown in standard 2-D culture conditions (*P < 0.05 
compared to “2-D Control”). (D) Growth of cells extracted from silica gels after immobilization 
for 3 days and control cells cultured in 2-D. (E) Heatmap of log2FC of gene expression in cells 
immobilized for one or three days relative to control cells. (F,G) Gene ontology enrichment 
analysis using genes significantly upregulated (green) or downregulated (red) in “Day 1” (F) or 
“Day 3” (G) of immobilization relative to 2-D controls. 
 
 
Figure 2.3: Percentage of Ki67-positive OVCAR-3 cells in silica gels decreases over time. 
Fluorescence images of immunostaining of nuclei (DAPI, blue) and Ki67 (red) at Day 0 and Day 




Figure 2.4: Surviving OVCAR-3 cells within silica gels do not exhibit senescence. Senescence-
associated β-galactosidase staining was used to label senescent cells. (A) Human foreskin 
fibroblasts at high passage number were used as a positive control. (B-D) Images comparing 
staining of OVCAR-3 cells grown in 2-D (B) or immobilized within silica gels at Day 0 (C) and 






Figure 2.5: Immobilized cells can be extracted from silica gels and resume proliferation after 
being re-seeded in 2-D culture conditions. Primarily single cells adhered to flasks 24 hours after 
extraction and continued to grow in small colonies, which was clearly seen by four days post-
extraction, and exhibited similar morphology as cells maintained in standard 2-D culture. (A,B) 
Phase-contrast images at 10x magnification of cells on 2-D surface 24 hours (A) or 4 days (B) after 
extraction. (C,D) Phase-contrast images at 4x magnification 1 week (C) or 2 weeks (D) after 
extraction. Scale bar indicates 400 µm and 1000 µm for 10x and 4x images, respectively.   
 
This demonstration of encapsulation in a stiff biomaterial prompting cell cycle exit 
recapitulates previous studies where gels derived from organic materials, such as collagen80 
or fibrin81, showed increasing stiffness results in slowed cell growth and metabolism. Here, 
the silica gels are advantageous as they do not allow for subsequent growth or division 
once cells are encapsulated, providing a harsh environment that causes most cells to 
quickly die. Another advantage of these silica gels is that encapsulated OVCAR-3 cells are 
unable to degrade the silica matrix, while gels derived from natural materials may weaken 
from enzymatic degradation. Minimal protein amounts in the starting silica gel matrix also 
provides less sites for cell adhesion and an increasingly difficult environment for these 
cells, which may result in survival of those more likely to undergo growth arrest and resist 
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apoptosis. Previously, 3-D bladder cancer spheroids cultured on low-adhesion 
aminoglycoside-derived hydrogels showed greater cell cycle arrest with increasing storage 
modulus82. Another study has investigated ovarian cancer cell migration, invasion, and 
growth in  cross-linked hyaluronan gels to determine whether the material could inhibit 
cancer cell adhesion and implantation in the pelvic cavity in vivo118. Here, we showed the 
immobilization of cells in stiff silica gels – which also limits their growth and division – 
results in survival of cells which have entered a dormant state, potentially to tolerate the 
stress of growth/mitotic inhibition upon confinement. 
 
2.3.2 Immobilization selects for a unique subpopulation with enhanced ability to enter 
dormancy  
To test the hypothesis that immobilization selects for cells with a greater propensity to enter 
dormancy in order to survive the stress of physical confinement, we re-immobilized cells 
extracted from the silica gels. Immediately prior to re-immobilization, we confirmed via 
Ki67 expression that the extracted cells were as proliferative as control cells maintained in 
2-D culture (Fig. 2.6A). Despite being proliferative just before returning to physical 
confinement, the extracted cells were found to have enhanced viability upon re-
immobilization (Fig. 2.6B). These results indicate that immobilization of OVCAR-3 cells 
selects for a population that may have enhanced pro-survival mechanisms and a greater 




Figure 2.6: Cells surviving silica gel immobilization demonstrate enhanced survival upon re-
immobilization relative to the original control population. Cells surviving immobilization for 
three days were extracted and cultured in 2-D for 1 week prior to immunostaining or re-
immobilization. (A) Percentage of Ki67-positive cells (number of Ki67-expressing cells (red) 
normalized to number of DAPI-labeled cells (blue)) from immunofluorescence images (merged 
images shown) compared to 2-D control cells. Scale bar indicates 200 µm. (B) Fold change in 
viable cell number relative to Day 0 after re-immobilizing extracted cells in silica gels relative to 
cells immobilized for the first time (Control) (*P < 0.05 compared to “Control” for each timepoint).  
 
2.3.3 Silica gel immobilization distinguishes OVCAR-3 cells with enhanced 
chemoresistance 
Because cells immobilized in silica gels exhibited differential gene expression associated 
with  dysregulated cell-substrate interactions, which are also thought to play a role in 
chemoresistance60,119, we investigated whether cells with enhanced chemoresistance would 
exhibit a higher propensity to enter dormancy and survive upon immobilization. To enrich 
for cells more resistant to platinum chemotherapy, OVCAR-3 cells were treated with 0.5 
µM cisplatin for 24 hours, and the surviving cells recovered for two weeks (Fig. 2.7). To 
verify that this procedure selected for chemoresistant cells, recovered cells were re-treated 
with the same dose of cisplatin, and cell viability after re-treatment (“Second Dose”) was 
compared to viability following initial treatment (“First Dose”, Fig. 2.8A). Initial treatment 
caused a significant decrease in viability over a 6-day period, while cells undergoing re-
treatment did not exhibit extensive cell death and continued to grow after Day 3, 
confirming their decreased sensitivity to the chemotherapy. Despite being in a proliferative 
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state prior to immobilization (Fig. 2.8B), after immobilization the cisplatin-resistant cells 
had markedly enhanced survival relative to untreated cells immobilized in gels (Fig. 2.8C), 
suggesting cells with enhanced chemoresistance may also have greater capacity to enter 
dormancy when stressed by immobilization and the silica gel environment. Ultimately, 
these results indicate that silica gel technology could be used as a method to distinguish 
ovarian cancer cells with enhanced chemoresistance.  
 
Figure 2.7: OVCAR-3 cells were treated with 0.5 µM cisplatin for 24 hours for significant cell 
death and recovery of a subset of cells. A 2 week-recovery period was required after drug removal 
because cells continued to detach and die for up to one week, and it was desired for cells to be back 
to proliferative state prior to encapsulation. (A) Timeline for selection of drug-resistant phenotype 
prior to silica gel immobilization or immunostaining. (B-G) Phase-contrast images of cells before 
treatment (B), immediately after drug was removed (C), and 2 days (D), 3 days (E), 1 week (F), 




Figure 2.8: Cisplatin-resistant OVCAR-3 cells have higher tolerance for immobilization and 
silica gel environment. (A) Cells retreated with a second dose of cisplatin are less susceptible to 
treatment than cells undergoing primary treatment, indicating the first dose selected for cisplatin-
resistant cells. Each treatment dose was 0.5 µM cisplatin for 24 hours, and cells receiving a second 
dose were allowed a 2-week recovery period before treatment with the second dose. Viable cell 
number at Day 0 is the number of live cells counted immediately after drug removal. (*P < 0.05 
compared to “First Dose”). (B) Cisplatin-resistant cells (“Treated”, i.e. treated with cisplatin and 
allowed to recover for 2 weeks) have similar Ki67 expression level as untreated cells. (C) Fold 
change in viable cell number relative to Day 0 of immobilized cisplatin-resistant cells and untreated 
control cells (*P < 0.05 compared to “Control” at each timepoint).  
 
2.3.4 RNA sequencing analysis shows cells surviving silica gel immobilization demonstrate 
signaling responses associated with chemoresistance 
RNA sequencing analysis of cells which survived immobilization in silica gels and were 
extracted (“Extracted”) and cells which survived cisplatin treatment (“Treated”) was 
performed to identify potential mechanisms that allow cells to survive within gels or evade 
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cisplatin treatment and which of these are shared between the two groups relative to 2-D 
untreated control cells (Fig. 2.9A). Many genes (1,424) were found to be differentially 
expressed in “Treated” cells relative to the 2-D untreated control, whereas only 328 genes 
were found to be differentially expressed in “Extracted” cells compared to the 2-D control. 
More than half of the genes differentially expressed in “Extracted” cells (63.7%, 209 genes) 
were also differentially expressed in “Treated” cells. Using Ingenuity Pathway Analysis 
(IPA), the Upstream Regulator function was used to discover transcriptional regulators 
which best explain the differential gene expression observed within the experimental data. 
The top 30 upstream regulators predicted to regulate the differential gene expression 
observed in both “Extracted” and “Treated” samples were primarily drugs or regulators 
associated with the inflammatory response (Fig. 2.9B). Interestingly, cisplatin was 
predicted as a regulator for “Treated” cells, as expected, but also for “Extracted” cells 
although they were never previously exposed to cisplatin, indicating that cells extracted 
from silica gels exhibit signaling responses as if they were treated by platinum 
chemotherapy. Fibroblast growth factor-2 (FGF-2) was additionally predicted to contribute 
to gene expression changes in surviving “Extracted” and “Treated” cells, and FGF-2 has 
previously been implicated as a mediator of chemoresistance by activating downstream 
survival pathways120,121 and linked to cellular dormancy in the context of breast 
cancer122,123. 
 
GO enrichment analysis of significantly upregulated genes in “Extracted” and “Treated” 
cells (Fig. 2.9C&D) gave terms typically associated with more invasive (e.g. cell motility, 
migration, chemotaxis) and chemoresistant (e.g. extracellular exosomes/vesicles) 
phenotypes124–126. Exosome and vesicle secretion are important for cell-cell 
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communication in the tumor microenvironment and are known to regulate metastasis and 
chemoresistance in cancer126. Further, previous work has shown that extracellular vesicles 
secreted by cisplatin-treated ovarian cancer cells can induce invasion and protection from 
chemotherapy in other cells pre-treated with these vesicles127. In “Treated” cells, 
defense/stress responses and interferon signaling terms were enriched, which was also 
observed in “Day 1” and “Day 3” immobilization groups, indicating potential similarities 
in downstream signaling responses to silica gel immobilization and cisplatin treatment. 
Genes previously associated with tumor initiating cells or the cancer stem cell theory (e.g. 
CD133, CD44, CD117, EpCAM, ALDH1A1) were not observed to be consistently and 
significantly enriched for in experimental groups relative to control cells37. Significantly 
downregulated genes enriched for terms related to the cell membrane, adhesion, and ECM 
in both “Extracted” and “Treated” cells. Previous studies have shown that cancer cells 
resisting apoptosis in non-adherent conditions are also more chemoresistant128–130. 
Additionally in ovarian cancer, non-adherent cancer spheroids either created in vitro or 
isolated from in vivo ascites fluid also demonstrate enhanced chemoresistance130–132. 
Moreover, ovarian cancer spheroids are thought to be a unique subpopulation of tumor 




Figure 2.9: OVCAR-3 cells selected by immobilization regulate genes similarly to cells 
surviving cisplatin treatment. (A) Heatmap of log2FC of gene expression in cells immobilized 
for three days, extracted, and cultured in standard 2-D conditions for two weeks (“Extracted”) and 
cells surviving treatment with 0.5 µM cisplatin for 24 hours and allowed to recover for 2 weeks in 
standard 2-D culture conditions (“Treated”) relative to control cells. (B) List of top 30 common 
upstream regulators (determined by average Z-score with P < 0.05) in “Extracted” and “Treated” 
cells based upon differentially expressed genes relative to control cells using Ingenuity Pathway 
Analysis. (C,D) Gene ontology enrichment analysis using genes significantly upregulated (green) 
or downregulated (red) in “Extracted” (C) or “Treated” (D) samples relative to 2-D controls. 
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Lastly, we compared the differential gene expression we observed in the “Extracted” 
population, which has been selected by immobilization to have a higher propensity to enter 
dormancy, with cancer cells from ovarian cancer patients who responded poorly to 
chemotherapy. Genes which were found to be significantly up- or downregulated in both 
the “Extracted” group relative to controls and chemoresistant patients relative to 
chemosensitive patients by Koti et al. and their fold change expression values were used 
in IPA to identify which pathways were most associated with these genes99. Canonical 
signaling pathways previously associated with poor clinical outcome and response to 
chemotherapy in ovarian cancer were identified (e.g. STAT3 Pathway, NF-κB 
Signaling)133–138, and most notably, pathways responsible for regulation and repair of 
DNA, which are proposed as key mechanisms of chemoresistance (e.g. NER Pathway, 
BER Pathway, etc.), were also observed (Tables 2.2 & 2.3). Our findings demonstrate that 
cells extracted from silica gels experienced stresses inducing downstream signaling as if 
they were treated by cisplatin and display altered regulation of genes associated with 
pathways known to be important in chemoresistance.  
Table 2.2: Canonical signaling pathways identified using Ingenuity Pathway Analysis for 
differentially expressed genes that were commonly up- or down-regulated between chemoresistant 
versus chemosensitive patients in Koti et al. (2013) and between our OVCAR-3 cells which 
survived immobilization and were extracted from silica gels (“Extracted”) versus control OVCAR-






Table 2.3: Canonical signaling pathways identified using Ingenuity Pathway Analysis for 
differentially expressed genes that were commonly up- or down-regulated between chemoresistant 
versus chemosensitive patients from the Koti et al. (2013) in silico analysis of The Cancer Genome 
Atlas ovarian cancer patient datasets and between our OVCAR-3 cells which survived 





2.3.5 OVCAR-3 cells selected by silica gel immobilization exhibit enhanced 
chemoresistance even when proliferative 
Because RNA sequencing analysis showed a significant overlap between dormancy-
capable cells and chemoresistant phenotypes, we investigated whether dormancy-capable 
cells would be more resistant to cisplatin chemotherapy. Surviving OVCAR-3 cells were 
extracted from silica gels following three days of immobilization, and one week post-
extraction they were treated with 0.5 µM cisplatin for 24 hours (Fig 2.10A, Scheme i). 
These extracted (dormancy-capable) cells demonstrated enhanced resistance to cisplatin 
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treatment – despite being proliferative (Fig. 2.6A) – relative to control cells which were 
never previously encapsulated (Fig. 2.10B). Interestingly, when OVCAR-3 cells induced 
into quiescence via hypoxia96,139 or serum starvation97 were treated with cisplatin, these 
cells exhibited enhanced chemoresistance (Fig. 2.11), consistent with earlier reports 
61,140,141. However, after returning to a proliferative state upon removal of the stress (Fig. 
2.10A, Scheme ii), these cells no longer had a survival advantage upon cisplatin treatment 
(Fig. 2.10C&D). These results demonstrate the uniqueness of physical confinement stress 
in silica gels, as it selects for cells which are chemoresistant even after the stress is lifted. 
This is further supported by our RNA sequencing analysis of “Extracted” cells, which 
demonstrated they regulate genes as if they had been treated with cisplatin and exhibit 
downstream signaling similar to “Treated” cells which survived cisplatin chemotherapy. It 
is possible that silica gels are a significantly harsher environment than hypoxia or serum 
starvation, and the stresses of physical confinement cause the majority of encapsulated 
cells to die, allowing for more efficient selection. Further, extracted cells may have 
enhanced chemoresistance due to mechanisms induced by growth inhibition and 
dysregulated cell-ECM substrate interactions experienced within gels. These cells may be 
able to mitigate pro-apoptotic signals that would be initiated under these stressful 
conditions and may instead sustain pro-survival pathways. The ability to resist 
programmed cell death would also be useful in resisting DNA damage-induced apoptosis 
via chemotherapy and could be a potential means for cells surviving confinement to also 
survive cisplatin treatment. Whether cells selected by immobilization are a unique 
subpopulation with innate capabilities or whether survival within silica gels is a learned 





Figure 2.10: Silica gel immobilization selects for cells that are more chemoresistant even while 
proliferative. (A) Timeline for cisplatin treatment studies of cells either (i) surviving silica gel 
immobilization or (ii) recovered from hypoxia treatment or serum starvation. Recovery periods of 
three days after hypoxia or serum starvation and one week post-extraction allowed for similar cell 
densities and return to a proliferative state at the start of cisplatin treatment. (B) Response to 
cisplatin treatment of cells surviving silica gel immobilization (“Extracted+Cisplatin”) relative to 
cells maintained in 2-D culture conditions (“2-D+Cisplatin”). Fold change in viable cell number 
indicates cell number at Day 3 post-cisplatin treatment relative to cell number before drug treatment 
(*P < 0.05 relative to 2-D). (C,D) Fold change in viable cell number for cells recovered from (C) 
hypoxia (“Recovered Hyp+Cisplatin”) or (D) serum starvation (“Recovered SS+Cisplatin”) and 
treated with 0.5 µM cisplatin for 24 hours relative to proliferating cells grown in standard culture 
conditions (“Cisplatin”) after treatment. Fold change in viable cell number indicates cell number at 
Day 3 post-cisplatin treatment relative to untreated controls for each respective condition (*P < 









Figure 2.11: OVCAR-3 cells induced into a quiescent state are less susceptible to cisplatin 
treatment. (A) Percentage of Ki67-positive cells (number of Ki67-expressing cells normalized to 
number of DAPI-labeled cells) in cells cultured in 1% oxygen (“Hypoxia”) or serum-free media 
(“Serum Starvation”) conditions over a one-week period (*P < 0.05 compared to previous 
timepoint). Quiescent cells were obtained by culturing cells in 1% oxygen conditions or serum-free 
media for 3 days prior to drug addition. (B,C) Comparison of fold change in viable cell number for 
(B) hypoxia-treated cells (“Hyp+Cisplatin”) or (C) serum-starved cells (“SS+Cisplatin”) against 
cells grown in standard 10% FBS-supplemented media conditions (“Cisplatin”) following 
treatment with 0.5 µM cisplatin for 24 hours. Fold change in viable cell number indicates cell 
number at Day 3 post-cisplatin treatment relative to untreated controls for each respective condition 
(*P < 0.05 compared to “Cisplatin”). 
 
2.3.6 Silica gel platform distinguishes cells with enhanced chemoresistance in other cell 
lines and towards taxane agents 
SKOV-3, another commonly used ovarian cancer model cell line for drug treatment study, 
ovarian adenocarcinoma cells were immobilized in silica gels to ensure that selection of 
cells with quiescent behavior and enhanced chemoresistance was not specific to OVCAR-
3 cells. The number of viable SKOV-3 cells significantly decreased over time once 
immobilized in silica gels (Fig. 2.12A). The percentage of Ki67-positive SKOV-3 cells 
also decreased over time in gels (Fig. 2.12B), and surviving cells could be extracted and 
cultured in 2-D. SKOV-3 cells are known to be more resistant to cisplatin than OVCAR-3 
cells142 and required a higher dose (5 µM) of cisplatin for significant cell death with 
recovery of a small chemoresistant subpopulation. Upon immobilization in silica gels, this 
cisplatin-resistant SKOV-3 cell population exhibited enhanced survival relative to control 
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cells with no previous drug treatment (Fig. 2.12C), consistent with the OVCAR-3 results. 
In separate studies, SKOV-3 cells surviving immobilization (dormancy-capable) were 
extracted from gels and found to have decreased sensitivity to cisplatin (Fig. 2.12D) along 
with enhanced viability upon re-immobilization (Fig. 2.12E), similar to OVCAR-3 cells. 
These results demonstrate that silica gel technology may be used to select for cells with 
enhanced chemoresistance and propensity to enter dormancy across ovarian cancer cell 
lines and may even show promise for application towards other cancer types.  
 
 
Figure 2.12: Selection of unique subpopulation via silica gel immobilization is also observed 
with SKOV-3 ovarian cancer cell line. (A) Calcein AM staining of viable SKOV-3 cells (green) 
immobilized for 0, 1, 2, 3, 5, and 7 days within silica gels. Scale bar indicates 400 µm. (B) 
Percentage of Ki67-positive SKOV-3 cells within silica gels over a three-day period (*P < 0.05 
compared to previous timepoint). (C) Fold change in viable cell number relative to Day 0 of 
immobilized cisplatin-resistant SKOV-3 cells and untreated control cells (*P < 0.05 compared to 
“Control” at each timepoint). (D,E) SKOV-3 cells surviving immobilization for 24 hours were 
extracted and cultured in 2-D for 1 week and used to find (D) the fold change in viable cell number 
three days after 5 µM cisplatin treatment for 24 hours relative to before treatment (*P < 0.05 
compared to “2-D”) and (E) the fold change in viable cell number relative to Day 0 after re-
immobilizing extracted SKOV-3 cells in silica gels relative to proliferating cells immobilized for 




The taxane-based chemotherapeutic paclitaxel was also investigated in combination with 
silica gel immobilization, as addition of taxane agents in combination with platinum 
chemotherapy has been the standard regimen for the last decade143. OVCAR-3 cells 
extracted from silica gels were found to have decreased susceptibility to paclitaxel 
treatment relative to 2-D control cells, even though these extracted cells were proliferating 
at time of paclitaxel addition (Fig. 2.13A). Again, this result demonstrates that the 
subpopulation surviving immobilization has enhanced chemoresistance but not only 
towards platinum-based agents. Further, treatment of OVCAR-3 cells with paclitaxel 
followed by a two-week recovery period allowed for selection of a more paclitaxel-
resistant population (Fig. 2.14). This population demonstrated significantly enhanced 
survival relative to untreated cells upon immobilization in silica gels (Fig. 2.13B), further 
demonstrating the ability of silica gels to identify ovarian cancer cells less susceptible to 
multiple types of chemotherapy. 
 
 
Figure 2.13: Extracted cells are less sensitive to paclitaxel, and paclitaxel-resistant cells 
exhibit enhanced survival upon immobilization. (A) Fold change in viable OVCAR-3 cell 
number three days after 30 nM paclitaxel for 24 hours relative to before treatment (*P < 0.05 
compared to “2-D”). (B) Fold change in viable cell number relative to Day 0 of immobilized 
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paclitaxel-resistant OVCAR-3 cells and untreated control cells (*P < 0.05 compared to “Control” 
at each timepoint).  
 
 
Figure 2.14: OVCAR-3 treatment with multiple doses of paclitaxel results in survival of a 
subset of cells that can recover and are less susceptible to an additional round of treatment. 
(A) Timeline for selection of more paclitaxel-resistant phenotype prior to silica gel immobilization. 
(B) Cells treated with a third dose of paclitaxel are less susceptible to treatment than cells 
undergoing secondary treatment. Each treatment dose is 30 nM paclitaxel for 24 hours, and cells 
receiving the third dose were allowed a 2 week-recovery period before treatment with the third 
dose. Viable cell number at Day 0 is the number of live cells counted immediately after drug 
removal. (*P < 0.05 compared to “Second Dose”). 
 
These last findings demonstrate the broad applicability of our physical confinement 
approach using stiff silica gels to investigate a unique subset of cells exhibiting dormant 
behavior upon immobilization and enhanced chemoresistance once removed from gels. We 
also showed cells surviving immobilization and extracted from silica gels were found to 
have enhanced viability upon re-immobilization, indicating these cells are distinct from the 
original population. Further, RNA sequencing analysis revealed that extracted cells also 
exhibit downstream signaling activity as if previously exposed to cisplatin, and 
differentially expressed genes resulted in terms associated with a more chemoresistant 
phenotype using GO analysis.  While cells released from quiescence using other in vitro 
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platforms did not exhibit enhanced chemoresistance, cells selected by silica gels were less 
susceptible to platinum and taxane agents despite being in a proliferative state. This finding 
provides evidence that cells which have an enhanced ability to enter dormancy, not just 
cells that are quiescent at the time of treatment, may be a primary cause of chemoresistance. 
Future studies investigating pathways initiated by cells surviving immobilization which are 
also common to cells surviving cisplatin treatment could further elucidate the interplay 
between ability to enter dormancy and chemoresistance and ultimately identify new 
therapeutic targets for ovarian cancer. Moreover, as our results showed distinct behavior 
of cisplatin- and paclitaxel-resistant cells upon immobilization, future work immobilizing 
ovarian cancer cells isolated from patient biopsies would determine whether silica gels 
could be a facile method for identifying patients with increased risk of recurrence.   
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Chapter 3: Iron oxide-loaded polymer scaffolds for non-invasive 
hyperthermic treatment of infiltrated cells 
 
Adapted with permission from “T. Lam, A. Moy, H. R. Lee, Q. Shao, J. C. Bischof, and S. 
M. Azarin; Iron oxide-loaded polymer scaffolds for non-invasive hyperthermic treatment 
of infiltrated cells, AIChE Journal, (2020) DOI: 10.1002/aic.17001” Copyright 2020 John 
Wiley & Sons, Inc. 
 
3.1 Introduction 
Another clinical challenge in ovarian cancer treatment is the lack of alternative treatment 
options to chemotherapy. However, an innovative modality that may be promising for 
ovarian cancer and could address chemoresistance and recurrence is focal therapy. Focal 
therapy consists of using energy-based methods such as hyperthermia/thermal ablation, 
cryoablation, and irreversible electroporation to kill cells and has garnered interest as an 
innovative treatment modality for cancer144–147. Further, hyperthermia and thermal ablation 
modalities are credited as minimally invasive or non-invasive ways to treat tumors and can 
also aid in stimulating an immune response against the killed cancer cells144,145. In 
hyperthermia and thermal ablation, high temperatures in a localized region are used to 
denature essential cellular proteins and damage tissue/vasculature structures, with cell 
damage and death depending on both the temperature during treatment and the duration of 
treatment148. Hyperthermic treatments rely on maintaining therapeutic temperatures of 
roughly 43 to 47 °C for tens of minutes to hours, while thermal ablation is a more rapid 
process with temperatures in excess of 50 °C and treatment times on the order of minutes. 
These methods have previously been used to treat localized solid tumors in the liver, 
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kidney, lung, breast, prostate, and bone144. However, although these approaches have 
shown success towards treating solid tumors, they cannot be readily applied to cancers that 
are often in a disseminated form, such as ovarian cancer. As mentioned in Chapter 1, 
ovarian cancer is often not diagnosed until it has reached an advanced stage, where cancer 
cells are often dispersed throughout the abdominal cavity of the patient22,73. The 
disseminated nature of this disease has made treatment difficult, and while the overall 
survival rate for ovarian cancer patients is only 20 to 30%143, patients whose cancer is 
confined to the ovaries have a better prognosis, with up to 90% being cured with existing 
treatments4.  
 
A potential way to apply focal therapy to advanced stage ovarian cancer is to use a 
biomaterial implant to localize disseminated cells to a targetable site prior to treatment.  
Previous studies have demonstrated that porous scaffolds fabricated from poly(lactide-co-
glycolide) or poly(ε-caprolactone) (PCL) could recruit and capture metastatic breast cancer 
cells in vivo76,77. Further, De la Fuente et al. implanted polystyrene/PCL-based scaffolds in 
the intraperitoneal cavity of mice and observed localization of SKOV-3 ovarian cancer 
cells at the scaffold, resulting in a decrease in tumor cell number at metastatic sites such as 
the pancreas and gonadal fat pad in a disseminated ovarian cancer model75. It was also 
shown that addition of recruitment moieties to the scaffold enhanced localization of 
disease, and its subsequent surgical removal significantly enhanced survival, likely by 
lowering the disease burden within the body75. However, another strategy in which the 
localized cancer cells could be destroyed at the scaffold site in situ using hyperthermic 
treatment would be advantageous to minimize additional invasive procedures. 
Furthermore, by destroying the cancer cells in situ using hyperthermia, the immune system 
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then has the ability to recognize cancer-specific antigens and garner anti-tumor 
immunity145. Overall, coupling focal therapy with biomaterial implants is desirable so that 
cancers which do not present in the form of a primary tumor (e.g. blood cancers) or are 
often disseminated (e.g. ovarian cancer) can be susceptible to this type of treatment. 
 
Previous studies have demonstrated the ability to incorporate energy-absorptive materials 
within a biomaterial implant for successful heating. In vitro killing of HeLa cervical cancer 
cells has been shown using NIR laser irradiation of gelatin and gold nanoparticle composite 
scaffolds149. Studies with alginate hydrogels loaded with polydopamine and element-doped 
bioactive ceramic glass scaffolds have also exhibited successful in vivo destruction of 
breast and bone cancers, respectively150,151. More recently, focal therapy methods have 
been coupled with biomaterial scaffolds which have previously been used to recruit 
metastatic cancer cells. Non-invasive hyperthermia treatment of infiltrated cells was 
successfully completed in vivo using porous PCL scaffolds with an embedded aluminum 
disk under an alternating magnetic field85. Although heating of cells within the scaffold 
was achieved, the temperature gradient resulting from a single thermal seed at the center 
of the cylindrical scaffold requires longer treatment times to reach therapeutic temperatures 
at the radial edge of the scaffold and results in elevated temperatures in a significant region 
of surrounding tissue due to the scaffold geometry. Because of this drawback, we sought 
to investigate a scaffold design that still utilizes the advantages of non-invasive 
hyperthermia but exhibits more uniform heating via a distributed heat source throughout 
the PCL scaffold. 
 
Magnetic materials have been investigated for thermal treatment in cancer, where magnetic 
nanoparticles are injected systemically or directly into the tumor and will generate heat in 
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the presence of an alternating magnetic field152.  Numerous types of magnetic nanoparticles 
have been investigated including ones derived from cobalt, nickel, and iron; however, iron 
oxide is most commonly used because of its high magnetic moment  and superior 
biocompatibility in comparison to other materials153,154. Initial studies characterizing 
magnetic particle heating carried out by Gilchrist et al. demonstrated that iron oxide was 
the most promising and exhibited no significant cytotoxic effects when administered to the 
lymph nodes in canines155. Since then, iron oxide particles alone or with various coatings 
(e.g. dextran, starch, amino-silane) have also been investigated for heating capability under 
alternating magnetic fields in the context of glioma156, breast157–159, and prostate 
cancers160,161. Furthermore, iron oxide has previously been incorporated into 3-D printed 
mesoporous bioactive glass/PCL scaffolds, resulting in heating when placed in an 
alternating magnetic field162. The clinical feasibility and safety of thermal therapy using 
iron oxide particles in humans has also been investigated. Prostate cancer patients received 
intratumoral delivery of iron oxide particles and were treated weekly for six weeks under 
an alternating magnetic field, and therapeutic temperatures were achieved within the 
tumors, demonstrating feasible clinical hyperthermia treatment using iron oxide163,164. In 
patients exhibiting recurrent glioblastoma multiforme, iron oxide delivered intracranially 
provided increased intratumoral temperatures under an alternating magnetic field with 
minimal or no adverse side effects165. Iron oxide has also been widely used for other 
biomedical and cancer applications such as MRI/diagnostics and drug delivery, 
demonstrating both its vast utility and safety in the clinic166.  
 
Given the ability to non-invasively generate heat from iron oxide under an alternating 
magnetic field and its widespread biomedical applications, we sought to incorporate iron 
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oxide into microporous PCL scaffolds previously shown to recruit disseminated breast 
cancer cells. Upon facile incorporation of bulk iron oxide particles into our scaffold 
fabrication protocol, iron oxide-loaded scaffolds exhibited magnetic behavior and heating 
under an alternating magnetic field, and ID8 ovarian cancer cells were successfully killed 
within these scaffolds in vitro. Further, iron oxide-loaded scaffolds were implanted into the 
intraperitoneal cavity of female mice and non-invasive hyperthermic treatment of cells 
within iron oxide-loaded scaffolds was demonstrated. These results show non-invasive 
hyperthermia can be used with a biomaterial scaffold in the intraperitoneal cavity, and iron 
oxide-loaded scaffolds could be used as a novel treatment modality towards disseminated 
ovarian cancer cells in the future.    
 
3.2 Materials and Methods 
3.2.1 Fabrication of iron oxide-loaded scaffolds 
For PCL-only and iron oxide-loaded scaffolds, PCL microspheres were fabricated as 
described previously77. Iron oxide-loaded PCL scaffolds were fabricated by mixing the 
desired amount of iron oxide powder (0.5 to 2.0 mg of spherical, < 44 μm Fe3O4 particles, 
Lansco 8330M) with 3 mg PCL microspheres and 90 mg (250-425 µm) sieved salt particles 
then thoroughly mixed. The mixture was loaded into a 5 mm steel die (Specac) and then 
pressed to 1000 PSI for 45 seconds using a mechanical press. Scaffold disks were then 
heated at 60 °C for 5 minutes on each side prior to gas foaming overnight. PCL-only or 
iron oxide-loaded scaffolds were placed in deionized water on a shaker for 1.5 or at least 3 
hours, respectively, to leach out the salt. Lastly, all scaffolds were sterilized in 70% ethanol, 
rinsed with sterile water, and dried prior to storage before use in experiments.   
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3.2.2 Scanning electron microscopy (SEM) 
Cross-sections of iron oxide-loaded scaffolds were coated with a 10 nm-thick palladium 
layer using an EM ACE600 sputter coater (Leica) and then imaged using a cold field 
emission gun scanning electron microscope (Hitachi S-4700, Hitachi High-Technologies 
Corp.) at 5000 V accelerating voltage. 
 
3.2.3 Radiofrequency heating studies 
To generate an alternating magnetic field (10.0, 20.8, and 30.5 kA/m), a 1 kW inductive 
heating system with a water-cooled, 2.75 turn copper coil was used (Ameritherm Inc.). Iron 
oxide-loaded scaffolds were placed in 1 mL of deionized water in a cryovial wrapped in 
nitrile foam insulation to decrease the amount of conductive heating from the coil, and it 
was positioned so that the scaffold was in the center of the coil (Fig. 3.1). A fiber optic 
temperature probe (Qualitrol Company LLC) was placed in the center of the scaffold and 
used to measure temperature over time. Any background temperature rise from these 
studies, as measured in a deionized water blank, was subtracted for the final results. All 
tests for these studies were 15 minutes in duration.  
 
Figure 3.1: Schematic of experimental setup for temperature rise studies. Iron oxide-loaded 
scaffolds were placed in 1 mL of deionized water inside a cryovial and positioned to be at the center 
of a water-cooled copper coil (gray). A fiber optic temperature probe (yellow) was placed through 




3.2.4 In vitro cytotoxicity studies 
Mouse ID8 ovarian cancer cells were a kind gift from Dr. Katherine Roby167  and were 
cultured in Dulbecco’s Modified Eagle’s Medium (Millipore Sigma D6429) with 4% fetal 
bovine serum (Thermo Fisher Scientific), 1% insulin-transferrin-sodium selenite 
supplement (Millipore Sigma), and 1% penicillin-streptomycin (Thermo Fisher Scientific). 
For each scaffold, 100,000 ID8 ovarian cancer cells in 20 µL of 5 mg/mL Matrigel 
(Corning) solution were loaded onto sterilized PCL-only or iron oxide-loaded scaffolds 
and placed in a 37 °C and 5% CO2 incubator for 5 minutes. Cell-loaded scaffolds were then 
moved to wells of a 48-well plate with fresh ID8 culture media and stored in the incubator 
until assay timepoints. 
 
At each timepoint for the AlamarBlue assay, the culture media surrounding scaffolds was 
carefully aspirated, and 300 µL of 10% AlamarBlue solution (Thermo Fisher Scientific), 
diluted in fresh ID8 culture media, was added to each well. After incubation under 37 °C 
and 5% CO2 for 1 hour, 100 µL of the AlamarBlue solution was collected and placed in a 
well of a black 96-well plate. Fluorescence of each sample was read with 560 nm excitation 
and 590 nm emission using a BioTek Synergy H1 microplate reader. Remaining 
AlamarBlue solution was aspirated from the wells and fresh ID8 culture media was added. 
 
3.2.5 Iron release (Ferrozine) assay 
Iron oxide-loaded scaffolds were placed in 1 mL of phosphate buffered saline (PBS, 
Thermo Fisher Scientific) in a 24-well plate placed under 37 °C and 5% CO2 conditions. 
Every 7 days, all of the PBS solution was collected and stored at 4 °C, and 1 mL of fresh 
PBS was carefully added to each well. After 6 weeks, the iron oxide-loaded scaffolds were 
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then transferred to fresh PBS and treated under an alternating magnetic field for 15 minutes 
at 30.5 kA/m and 360 kHz, and the PBS solution after treatment was collected for testing. 
 
Following the manufacturer’s protocol, the Iron Colorimetric Assay Kit (Ferrozine 
Method) from AdipoGen (JAI-CFE-005) with a sensitivity range of 5 – 1000 μg/dL was 
used to investigate the amount of iron released. Briefly, 40 µL of blank (distilled water), 
standard, or sample was added in triplicate to a clear flat bottom 96-well plate. 200 µL of 
R-1 reagent was added to each well and incubated for 5 minutes at room temperature, 
followed by reading the absorbance of each well at 560 nm using a BioTek Synergy H1 
microplate reader. 8 µL of R-2 reagent was then added to each well and incubated for 5 




3.2.6 In vitro and ex vivo heating studies 
For in vitro heating studies, 400,000 ID8 ovarian cancer cells in 20 µL of 5 mg/mL Matrigel 
solution were loaded onto sterilized scaffolds and placed in a 37 °C and 5% CO2 incubator 
for 5 minutes. For ex vivo heating studies, tissue-laden iron oxide-loaded scaffolds were 
collected from the intraperitoneal cavity of mice 6-7 weeks post-implantation. Negative 
control scaffolds for cell death (“IO no heat”) were left in standard culture conditions at 
37°C and 5% CO2 in ID8 culture media. Scaffolds receiving hyperthermic treatment (“IO 
heat”) were placed in 1 mL of PBS and placed in the presence of an alternating magnetic 
field for 15 minutes at 30.5 kA/m and 360 kHz.  
 
To determine cell viability, a WST-1 assay was used. Each scaffold was minced with 
microscissors in 500 µL of fresh ID8 culture media with 50 µL WST-1 reagent (Takara 
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Bio) in a 48-well plate and incubated at 37 °C and 5% CO2 for 1.5 hours. After incubation, 
the samples were centrifuged, and 400 µL of the supernatant solution was passed through 
a 70 µm mesh filter (Corning). Supernatant absorbance for each scaffold and media only 
controls (500 µL of fresh ID8 culture media with 50 µL WST-1 reagent incubated for 1.5 
hours) was read in triplicate at 440 nm using a BioTek Synergy H1 microplate reader.  
 
3.2.7 Scaffold implantation and in vivo heating 
All animal studies were approved and conducted following the guidelines under the 
University of Minnesota’s Institutional Animal Care and Use Committee. Female 
C57BL/6J mice were purchased from The Jackson Laboratory and were around 7-8 weeks 
old at time of scaffold implantation. For surgical implantation of scaffolds, mice were 
anesthetized and laid on their back so an incision at the abdominal midline could be made 
in the skin, followed by an incision in the peritoneal wall. One PCL-only or iron oxide-
loaded scaffold was carefully placed adjacent to the intraperitoneal side of the wall to the 
left of the incision, and then the peritoneal wall and skin were each closed with sutures. 
For in vivo heating studies, mice with iron oxide-loaded scaffolds implanted for 6-7 weeks 
were anesthetized, and the hair on the belly was removed to visually locate the iron oxide-
loaded scaffolds under the layers of skin. Anesthetized mice were carefully placed on their 
back underneath the copper coil on a height-adjustable platform. Due to the size constraints 
of the coil (1.75 cm inner diameter), this placement of the mice was used to position the 
scaffold located in the intraperitoneal cavity as close to the center of the coil as possible. 
For each mouse, the treatment period was 15 minutes at 26.4 ± 0.5 kA/m and 360 kHz 
fields, and the magnetic field strength at this position (~ 1-2 mm beneath the bottom of 
coil) was determined using a 2D HF Magnetic Field Probe (AMF Life Systems) and 
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TDS2002 Digital Oscilloscope (Tektronix). Treated scaffolds were harvested 3 days post-
treatment for histological analysis. 
 
3.2.8 Histological analysis 
Scaffolds implanted in the intraperitoneal cavity of mice were harvested for histological 
analysis and immediately placed in 10% buffered formalin solution (Millipore Sigma) at 
least overnight prior to transfer to 70% ethanol and embedding in paraffin blocks. Scaffolds 
were sliced into 4 µm sections using a HM 315 microtome (Microm) then stained with 
hematoxylin and eosin (H&E) dyes. Stained scaffold sections were imaged using an EVOS 
FL Auto Microscope (Thermo Fisher Scientific). 
 
3.2.9 Statistical analysis 
Data are shown as mean ± standard deviation of three or more biological replicates. For 
the AlamarBlue assay, a two-way ANOVA in GraphPad Prism software was used to 
determine significance between “PCL-only” and “IO-loaded” groups. P-values were 
determined from Student’s unpaired t-test for the radiofrequency heating studies and WST-




3.3.1 Facile incorporation of iron oxide into microporous polymer scaffolds 
To establish more uniform heating than our previous aluminum disk-PCL scaffold 
design85, incorporation of iron oxide particles throughout porous PCL scaffolds was 
investigated. Microporous PCL scaffolds have previously been fabricated by pressing a 
PCL and salt mixture into a 5 mm disk using a mechanical press, followed by other post-
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processing steps including leaching of the salt to create the porous architecture77. To easily 
incorporate and control the amount of iron oxide loaded into the scaffolds, iron oxide 
powder was directly weighed out and mixed with the initial salt and PCL polymer mixture 
(Fig. 3.2A). After soaking the fabricated scaffolds in water to leach out the salt, the iron 
oxide-loaded scaffolds maintained the dark black color of the scaffold prior to leaching, 
indicating successful loading and retention of iron oxide in the porous scaffolds. Successful 
loading of iron oxide was also confirmed by the fact that iron oxide-loaded scaffolds 
exhibited magnetic behavior and were able to adhere to the bottom of a strong neodymium 
magnet, while PCL-only scaffolds did not (Fig. 3.3A). Maintenance of the porous 
architecture was also a necessary design parameter of iron oxide-loaded scaffolds, as the 
pores allow for cell infiltration and consequently their destruction by hyperthermia. SEM 
imaging demonstrated that iron oxide-loaded scaffolds exhibited pores of expected size 
based on the sieved (250-425 µm) salt used (Fig. 3.2B&C). This simple method to 
incorporate iron oxide particles allowed for fine control of loading amount, which was 
visually observed by the color gradient of scaffolds loaded with increasing amounts of iron 




Figure 3.2: Iron oxide particles can easily be incorporated into microporous 
poly(caprolactone) (PCL) scaffolds. Iron oxide-loaded PCL scaffolds are 5 mm in diameter and 
have 250 – 425 µm porous architecture. (A) Schematic of fabrication process for iron oxide-loaded 
PCL scaffolds. (B,C) Scanning electron microscopy images of cross section of 2 mg iron oxide-





Figure 3.3: Iron oxide-loaded scaffolds exhibit magnetic behavior and can easily be loaded 
with varying amounts of iron oxide. (A) Image of iron oxide-loaded scaffold adhering to the 
bottom of a strong neodymium magnet while PCL-only scaffolds do not. (B) Image of PCL 




3.3.2 Heating of iron oxide-loaded scaffolds can be modulated with tunable parameters 
To confirm iron oxide-loaded scaffolds could heat in the presence of an alternating 
magnetic field, iron oxide-loaded scaffolds were submerged in 1 mL of deionized water 
and placed in the center of a copper coil attached to a 1 kW inductive heating system (Fig. 
3.1). A fiber optic temperature probe was placed through the center of the scaffold, and the 
system was run for 15 minutes to establish the temperature rise (Tfinal – Tinitial) of the 
scaffold in the presence of an alternating magnetic field. It was observed that increasing 
the amount of iron oxide loaded into the PCL scaffold (1.0, 1.5, and 2.0 mg) led to an 
increase in temperature rise (2.8 ± 0.6, 4.5 ± 1.1, and 7.2 ± 1.0 °C, respectively), which 
was expected (Fig. 3.4A). Additionally, the temperature rise increased (0.5 ± 0.3, 2.2 ± 0.5, 
and 6.5 ± 0.8 °C) with increasing magnetic field strength (10.0, 20.8, and 30.5 kA/m, 
respectively) when frequency and iron oxide amount were held constant (Fig. 3.4B). These 
results demonstrate that simple design and system parameters of the iron oxide-loaded 
scaffolds and the alternating magnetic field can be tuned for a desired temperature rise 
within the scaffold and consequently heating of infiltrated cells. Because greater iron oxide 
amounts and increasing magnetic field strength led to greater temperature rise, 2 mg iron 
oxide-loaded scaffolds in the presence of a 30.5 kA/m and 360 kHz alternating magnetic 





Figure 3.4: Heating of iron oxide-loaded scaffolds can be altered by tunable design and system 
parameters. (A) Temperature rise of iron oxide-loaded scaffolds with varying amounts of iron 
oxide under 30.5 kA/m field strength and 360 kHz frequency for 15 minutes. (B) Temperature rise 
of 2 mg iron oxide-loaded scaffolds under 360 kHz frequency for 15 minutes with various magnetic 
field strengths. *P-value < 0.05. 
 
3.3.3 Ovarian cancer cells can be killed by heat using iron oxide-loaded scaffolds 
After verifying the iron oxide-loaded scaffolds could heat in the presence of an alternating 
magnetic field, ID8 ovarian cancer cells in Matrigel were seeded into scaffolds to 
determine whether they could be killed by heat in vitro. First, to establish that the iron 
oxide loaded into scaffolds did not adversely affect loaded ovarian cancer cells, an 
AlamarBlue assay was used to determine whether cell proliferation was inhibited. Seeded 
ID8 ovarian cancer cells were able to proliferate in both types of scaffolds, and the growth 
of these cells in PCL-only and iron oxide-loaded scaffolds was not significantly different 
up to three days after seeding (Fig. 3.5A), suggesting the iron oxide incorporated into 
scaffolds did not cause cytotoxic effects. 
 
Seeded ID8 ovarian cancer cells in PCL-only and iron oxide-loaded scaffolds were then 
treated with an alternating magnetic field at 30.5 kA/m and 360 kHz for 15 minutes, and a 
WST-1 assay was used to determine whether seeded cells were effectively killed. Cells 
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seeded within iron oxide-loaded scaffolds that were left at 37 ºC and 5% CO2 conditions 
(“IO no heat”, negative control for cell death) had the greatest cell viability, while cells 
seeded within iron oxide-loaded scaffolds treated with the alternating magnetic field (“IO 
heat”) exhibited cell viability values similar to media only controls (positive control for 
cell death) (Fig. 3.5B). Ovarian cancer cells seeded within PCL-only scaffolds which were 
treated with the same field conditions (“PCL heat”) also exhibited some decrease in cell 
viability, although not as significant as the treated iron oxide-loaded scaffold group. This 
decrease in cell viability in PCL-only scaffolds is attributed to the imperfect insulation 
between the coil system and the vial containing the scaffold, resulting in some conductive 
heat transfer from the coil to the cells within the scaffold (Fig. 3.6). Overall, we were able 
to demonstrate that iron oxide-loaded scaffolds can be used to kill ovarian cancer cells 
seeded within the scaffold by hyperthermia. 
 
 
Figure 3.5: Iron oxide-loaded scaffolds are not cytotoxic and can kill ovarian cancer cells by 
hyperthermia in vitro. (A) Proliferation of ID8 ovarian cancer cells in PCL-only or iron oxide-
loaded scaffolds for up to 3 days after seeding using an AlamarBlue assay. Bars indicate mean fold 
change and standard deviation normalized to Day 1. A two‐way ANOVA determined there was no 
statistically significant difference between “PCL-only” and “IO-loaded” groups. (B) Viability of 
ID8 ovarian cancer cells seeded onto iron oxide-loaded scaffolds that were left in 37ºC and 5% CO2 
conditions (“IO no heat”), PCL-only scaffolds that were heated under an alternating magnetic field 
(“PCL heat”), and iron oxide-loaded scaffolds that were heated under an alternating magnetic field 
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(“IO heat”) using a WST-1 assay. No cell control of media only (“Media”) was used as a positive 
control for cell death. Decreases in 440 nm absorbance indicate decreases in cell viability. All 
treatments under an alternating magnetic field were for 15 minutes at 30.5 kA/m and 360 kHz 
fields. *P-value < 0.05 relative to “IO no heat” or “PCL heat”. 
 
 
Figure 3.6: Example of background heating of copper coil during treatment. Control tests with 
1 mL of deionized water only in a cryovial were completed, and the temperature rise after 15 
minutes at 360 kHz and various field strengths was determined using a fiber optic temperature 
probe. All temperature rise studies investigating iron oxide loading amount and field strength had 
water only control tests, and the background heating was subtracted off to give final values. 
 
3.3.4 Iron oxide-loaded scaffolds become infiltrated with cells after intraperitoneal 
implantation 
PCL-only and iron oxide-loaded scaffolds were next implanted into the intraperitoneal 
cavity of female C57BL/6J mice to compare the infiltration of cells into the porous 
architecture and verify that iron oxide-loaded scaffolds can become properly infiltrated 
when implanted in this location. Initially, scaffolds were harvested after 3-4 weeks of 
implantation for histological analysis, as this timepoint has previously been shown to 
provide sufficient cell infiltration for PCL-only scaffolds77,85,168. As expected, the PCL-
only scaffolds exhibited significant cell infiltration, as seen by the many nuclei visualized 
by hematoxylin and eosin (H&E) staining of PCL-only scaffold sections (Fig. 3.7A). 
However, it was evident from staining that iron oxide-loaded scaffolds demonstrated 
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decreased cell infiltration at 3-4 weeks post-implantation (Fig. 3.7B), suggesting a longer 
implantation period is needed for sufficient cell infiltration prior to treatment. After 6-7 
weeks of implantation, iron oxide-loaded scaffolds harvested for histology demonstrated 
enhanced cell infiltration and exhibited similar infiltration as the PCL-only scaffolds (Fig. 
3.7C). To verify that a sufficient amount of iron oxide would still be present within iron 
oxide-loaded scaffolds at this timepoint, an in vitro study of iron release from the scaffolds 
was performed. Negligible amounts of total iron released were observed after 6 weeks of 
scaffold incubation and subsequent heating in vitro (Fig. 3.8), indicating that there would 
be sufficient iron oxide present for non-invasive hyperthermic treatment after 6-7 weeks of 
implantation.  
 
Figure 3.7: Iron oxide-loaded scaffolds can become fully infiltrated with cells when implanted 
in vivo, although requiring a longer implantation time than PCL-only scaffolds. Scaffolds were 
implanted by the intraperitoneal wall for 3-4 or 6-7 weeks in female C57BL/6J mice.  (A-C) H&E 
staining of sections of a PCL-only scaffold (A), IO-loaded scaffold implanted for 3-4 weeks (B), 
or IO-loaded scaffold implanted for 6-7 weeks (C). Black areas seen in “IO-loaded” histological 





Figure 3.8: Iron oxide-loaded scaffolds exhibit negligible release of iron over a 6-week 
duration and after heating in vitro. The total amount of iron released was determined using a 
Ferrozine assay. Release was measured weekly for 6 weeks from 2 mg iron oxide-loaded scaffolds, 
which were placed in PBS and kept at 37 °C. At week 6, scaffolds were then treated with an 
alternating magnetic field for 15 minutes at 30.5 kA/m and 360 kHz. The additional amount of iron 
released after this treatment contributing to total iron released per scaffold is shown as “Heat” 
(red).    
 
3.3.5 Cells in tissue-laden iron oxide-loaded scaffolds can be killed by hyperthermia ex 
vivo 
To demonstrate that tissue-laden scaffolds could be successfully heated, iron oxide-loaded 
scaffolds were implanted in the intraperitoneal cavity of mice for 6-7 weeks, then harvested 
and placed in the center of the coil system for treatment in the presence of a 30.5 kA/m and 
360 kHz alternating magnetic field for 15 minutes. Tissue-laden iron oxide-loaded 
scaffolds which were treated (“IO heat”) exhibited cell viability similar to media only 
controls (“Media”, positive control for cell death) after hyperthermic treatment (Fig. 3.9). 
As expected, cells infiltrated within tissue-laden iron oxide-loaded scaffolds left at standard 
culture conditions (“IO no heat”, negative control for cell death) exhibited significantly 
higher viability. These ex vivo results are consistent with the in vitro studies using ID8 
ovarian cancer cells, and they further demonstrate that endogenous proteins and matrix 
deposited by infiltrated cells within implanted iron oxide-loaded scaffolds do not hinder 
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the ability of iron oxide-loaded scaffolds to effectively kill infiltrated cells under an 
alternating magnetic field. 
 
Figure 3.9: Cells within tissue-laden iron oxide-loaded scaffolds can be killed by heat ex vivo 
in the presence of an alternating magnetic field. Using a WST-1 assay, the viability of cells in 
tissue-laden scaffolds placed under standard culture conditions (37°C and 5% CO2, “IO no heat”) 
or after treatment for 15 minutes at 30.5 kA/m and 360 kHz (“IO heat”) was investigated. Media 
only controls were used as a no cell control (“Media”). *P-value < 0.05 relative to “IO no heat”.  
 
3.3.6 Infiltrated cells in iron oxide-loaded scaffolds can be killed non-invasively by 
hyperthermia in vivo 
Lastly, we sought to establish whether iron oxide-loaded scaffolds could be used to non-
invasively kill infiltrated cells by heat in the intraperitoneal cavity in vivo. Mice with iron 
oxide-loaded scaffolds implanted intraperitoneally for 6-7 weeks were used to ensure there 
was proper cell infiltration prior to treatment. Due to the size constraints of the coil, mice 
were carefully placed on their backs with the abdominal cavity placed beneath the coil 
(Fig. 3.10A) and were treated with 26.4 ± 0.5 kA/m magnetic field strength (Fig. 3.11) and 
360 kHz frequency for 15 minutes. Treated scaffolds were harvested three days post-
treatment for histological analysis. Upon H&E staining, it was observed that the number 
of nuclei present in mice with proper placement of treated iron oxide-loaded scaffolds 
significantly decreased, with primarily protein/matrix left behind (Fig. 3.10B&C) as 
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compared to 6-7 week-implanted iron oxide-loaded scaffolds that did not receive treatment 
(Fig. 3.7C). Importantly, some treated iron oxide-loaded scaffolds exhibited regions of 
effective heating (Fig. 3.10C), while other regions of the same treated scaffold had 
significantly more nuclei present (Fig. 3.10D). Because the field strength decreases 
significantly once outside the center of the coil (both axially and radially)169, these findings 
indicate sub-optimal placement of the iron oxide-loaded scaffold during treatment and 
demonstrate the importance of the scaffold’s position within the magnetic field for 
effective cell death. Overall, it was demonstrated that iron oxide-loaded scaffolds in the 
intraperitoneal cavity can be used for hyperthermic treatment of infiltrated cells both non-
invasively and in a relatively short treatment time in vivo. 
 
Figure 3.10: Cells within iron oxide-loaded scaffolds can be non-invasively killed in vivo in 
the presence of an alternating magnetic field. Iron oxide-loaded scaffolds were implanted into 
the intraperitoneal cavity of C57BL/6J mice for 6-7 weeks and then treated for 15 minutes at 26.4 
± 0.5 kA/m field strength and 360 kHz field frequency. Scaffolds were retrieved 3 days post-
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treatment. (A) Schematic of mouse and scaffold positioning relative to the coil system for 
hyperthermic treatment. The hair on the belly of mice was removed to approximate the location of 
the implanted iron oxide-loaded scaffold in order to position it as close to the bottom of coil as 
possible for treatment. (B-D) Examples of H&E stained sections of iron oxide-loaded scaffolds 
with successful treatment (B,C) and a region with partial treatment (D). Panels (C) and (D) are 




Figure 3.11: Magnetic field strength beneath coil for in vivo heating of iron oxide-loaded 
scaffolds was determined. The magnetic field strength in the radial center and ≈ 1-2 mm below 
the bottom of the coil was determined using a magnetic field probe. (A) Values of magnetic field 
strength at 15-second intervals during three tests (60-second duration total). (B) Average magnetic 
field strength for each 60-second test (black bars) and overall average magnetic field strength for 
all tests combined (striped bar, 26.4 ± 0.5 kA/m). 
 
3.4 Discussion 
Biomaterial implants which localize disseminated cancer cells are promising for ovarian 
cancer treatment, as this disease is often found in an advanced stage and thus in a highly 
disseminated form throughout the intraperitoneal cavity. Further, a biomaterial which can 
also locally, non-invasively, and repeatedly destroy cells by heat in the intraperitoneal 
cavity is of great interest due to the recurrent nature of ovarian cancer. Here, we 
incorporated iron oxide particles into porous PCL scaffolds previously shown to recruit 
cancer cells by mixing iron oxide particles with PCL microspheres and salt prior to 
mechanical pressing77,85. In our previous work, an aluminum disk was embedded in the 
center of these PCL scaffolds for hyperthermic treatment of infiltrated cells under an 
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alternating magnetic field85. However, using a single thermal seed within the scaffold will 
provide less uniform heating versus a scaffold design containing a heat source that is 
distributed throughout, such as iron oxide particles. Uniform scaffold heating allows for a 
lower maximum temperature needed within the scaffold for effective hyperthermia 
treatment of the entire scaffold, and a distributed heat source decreases the dependence of 
scaffold orientation (and its single thermal seed) with respect to the magnetic field on 
heating. In these studies, after leaching of salt and sterilization, iron oxide-loaded scaffolds 
were homogeneous in texture and color, indicating appropriate dispersion of iron oxide 
throughout and consequently suggesting more uniform heating for cell death than the 
previous design.  
 
Extensive work has been completed to characterize the heating of iron oxide particles upon 
placement within alternating magnetic fields154,170,171. Iron oxide particles are known to 
generate heat through eddy current and hysteresis losses when > 1 μm in size, 
superparamagnetic mechanisms such as Neel or Brownian relaxation losses when < ≈ 20 
nm, and hysteresis heating for those sized in between154. The iron oxide particles used here 
were spherical and sieved giving a < 44 μm size, and the use of iron oxide particle powder 
allowed for simple incorporation of iron oxide into the scaffold fabrication process along 
with easy modulation of loading amounts. Because each iron oxide particle acts as a 
thermal seed in the presence of an alternating magnetic field, larger concentrations of iron 
oxide lead to faster heating rates171, which was observed in the temperature rise studies 
here. The size and shape of iron oxide particles can also influence heating170–174, and testing 
various sizes or morphologies of iron oxide particles within porous PCL scaffolds could 
lead to scaffold designs with enhanced heating in future studies. Specifically, investigating 
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methods to incorporate and retain iron oxide nanoparticles into PCL scaffolds is of interest 
for optimized heating and/or reducing the iron oxide content in the scaffolds. It is also well 
understood that magnetic field parameters will influence the heating of iron oxide particles. 
Shah et al. observed greater temperature rise with increasing magnetic field strengths and 
frequencies for dextran-coated iron oxide particles171. Guardia et al. observed a similar 
trend where increasing field strength and frequency resulted in larger specific absorption 
rates (SAR) for iron oxide nanocubes172, with SAR values indicating the rate at which a 
material absorbs energy per unit mass. The temperature rise of iron oxide-loaded scaffolds 
containing iron oxide powder with size < 44 μm also increased with greater magnetic field 
strengths in this study. Previous work indicates that quadratic dependence of field strength 
may be possible, while a linear dependence of frequency on SAR values is expected for 
various magnetic nanoparticles172,175, suggesting further optimization of heating could be 
attained by testing iron oxide nanoparticles in PCL scaffolds under various magnetic field 
parameters. While the magnetic field strength has the dominant effect on heating, the field 
frequency is another parameter that could be optimized in the future if a greater temperature 
rise is desired for the iron oxide-loaded scaffolds.   
 
In vitro and in vivo studies have shown effective direct cell killing at temperatures between 
41 and 47 °C148,176,177. Additionally, it has been demonstrated that cell survival 
exponentially decreases with treatment time once temperatures reach and increase beyond 
43 °C177,178. From the temperature rise studies, the greatest temperature rise observed was 
≈ 7 °C, thus indicating potential temperatures of up to 43 °C in vivo. This temperature is 
suitable for the iron oxide-loaded PCL scaffolds due to the melting point of PCL (~10 to 
15 °C above physiological temperature)78, as significantly higher temperatures may cause 
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enhanced release of iron oxide and limit its potential for multiple hyperthermic treatments. 
Upon in vitro treatment of ID8 ovarian cancer cells within iron oxide-loaded scaffolds, cell 
viability decreased to that of media only controls. Consistent with the results reported here, 
3-D printed mesoporous bioactive glass/PCL scaffolds with iron oxide demonstrated 
significant temperature rise in the presence of an alternating magnetic field; however the 
cell killing capability of those scaffolds was not investigated162. In addition, Zhang et al. 
fabricated folic acid-functionalized gelatin scaffolds with iron oxide, which killed HeLa 
cervical cancer cells upon NIR laser irradiation in vitro179.  
 
For its potential application towards ovarian cancer, iron oxide-loaded scaffolds were 
implanted by the intraperitoneal wall to investigate cell infiltration into the porous 
architecture. This site for implantation is of interest because ovarian cancer metastases are 
typically confined within the intraperitoneal cavity, and ovarian cancer cells disseminated 
from the primary tumor will adhere to the peritoneum which lines the cavity wall and 
abdominal organs22. Previously, PCL-only scaffolds had been implanted into the 
subcutaneous space or wrapped in the gonadal fat pad within the intraperitoneal cavity, and 
3-4 weeks of implantation was sufficient for cell infiltration77,85,168. Here, PCL-only 
scaffolds exhibited many nuclei and deposited extracellular matrix within pores after 3-4 
weeks when attached to the intraperitoneal wall, but iron oxide-loaded scaffolds required 
6-7 weeks of implantation for similar levels of cell infiltration at this site. This decreased 
rate of infiltration is likely due to the low solubility of iron oxide in water, thus making the 
iron oxide-loaded scaffolds more hydrophobic, which will impact cell adhesion and 
consequently the rate of infiltration180. For in vivo applications, the advantage of a 
biomaterial implant containing iron oxide versus injection of free particles is that the iron 
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oxide can be directly placed within the intraperitoneal cavity in a high and localized 
concentration that is stable over a longer period of time. Iron oxide-loaded scaffolds could 
address the current challenges of traditional systemic delivery, such as fast clearance from 
the body and organ cytotoxicity due to the larger doses required to achieve sufficient 
concentrations at the targeted site78.  Incorporation of iron oxide into PCL scaffolds did not 
significantly alter ID8 ovarian cancer cell proliferation, suggesting no significant 
cytotoxicity. This is consistent with previous reports with non-cancerous cell lines and 
cancer cell lines arising from glia, breast, liver, and cervix demonstrating in vitro 
biocompatibility towards iron oxide particles when using concentrations ranging from 0.1 
to 50 μg/mL and toxicity occurring at a higher concentration of 100 μg/mL181,182. Further, 
iron oxide remained concentrated within the scaffold for up to 6 weeks and even after 
heating in vitro, and iron oxide particles should primarily be released only as the PCL 
polymer degrades, occurring through hydrolysis over the duration of months to years in 
vivo183,184. Additionally, the use of PCL polymer in this scaffold design and its slow 
degradation rate should allow for repeated use of non-invasive hyperthermic treatment due 
to the high retention of concentrated iron oxide within the scaffold.  
 
After implantation for 6-7 weeks in the intraperitoneal cavity, it was demonstrated that 
tissue-laden iron oxide-loaded scaffolds could be used to kill infiltrated cells ex vivo in the 
presence of an alternating magnetic field. These ex vivo results are distinct from the in vitro 
results where iron oxide-loaded scaffolds heated ovarian cancer cells in Matrigel, as the 
extracellular matrix density and proteins deposited by infiltrated cells within the scaffold 
pores will likely differ. Most importantly, this ex vivo study demonstrated that infiltrated 
cells could be killed within iron oxide-loaded scaffolds when placed in the center of the 
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coil, where the field is most uniform. In contrast, iron oxide-loaded scaffolds were 
investigated for hyperthermia potential in vivo but had to be placed underneath the coil 
during treatment due to size constraints of the coil. Once outside of the inductive coil, the 
magnetic field strength can vary during treatment, and it will decrease significantly at 
positions away from the center of the coil85,169.  When the scaffold was placed within the 
alternating magnetic field, killing of infiltrated cells could be accomplished, as evidenced 
by the decrease in number of nuclei through H&E staining. The observation that some 
regions within a scaffold were treated successfully while others had many remaining cells 
displays the importance of properly positioning the iron oxide-loaded scaffold within the 
magnetic field. To mitigate this, a larger coil in which the entire mouse could be placed in 
a uniform field volume during treatment would be useful for future studies, and this setup 
would be more representative of what is currently used in the clinic (e.g. MRI scanners). 
However, even though the iron oxide-loaded scaffolds had to be positioned outside of the 
coil for treatment, decreases in cell number were still observed. The scaffold design and 
magnetic field parameters should be further optimized for continued clinical translation, as 
the field strength and frequency (H×f) used for patients should be < 5×109 A/(m∙s)185,186. 
Potential options involve designing larger scaffolds allowing for increased iron oxide 
loading and thus achieving higher temperatures, or treatment duration could also be 
increased as these studies used treatment times of only 15 minutes. Clinical trials using 
hyperthermia in combination with other forms of treatment have consisted of hyperthermia 
treatment times of  ≥ 30 minutes at a desired maximum temperature and often last an hour 




In conclusion, iron oxide was incorporated into porous PCL scaffolds previously shown to 
recruit disseminated cancer cells by simple mixing of iron oxide particles with PCL 
microspheres and salt at the beginning of fabrication. These iron oxide-loaded scaffolds 
exhibited magnetic behavior and maintained their porous architecture, which is necessary 
for cell infiltration. Further, scaffold design and magnetic field parameters – such as iron 
oxide loading and field strength, respectively – that can easily be modulated were shown 
to influence temperature rise. Incorporation of iron oxide did not exhibit cytotoxicity 
against ovarian cancer cells but did allow for their destruction under an alternating 
magnetic field in vitro. Iron oxide-loaded scaffolds were implanted by the intraperitoneal 
cavity wall of female mice and exhibited extensive cell infiltration and extracellular matrix 
deposition in the porous architecture after 6-7 weeks. The infiltrated cells within iron 
oxide-loaded scaffolds could be killed both ex vivo and in vivo under an alternating 
magnetic field, demonstrating the therapeutic potential of iron oxide-loaded scaffolds to 
kill cells locally and non-invasively. The incorporation of iron oxide into biomaterials that 
can capture tumor cells enables application of hyperthermia to cancers that are 
disseminated, addressing the challenges of systemic delivery by facilitating a sufficiently 







Chapter 4: Characterizing recruitment potential of biomaterial 
scaffolds for cancer cell capture in an advanced stage ovarian 
cancer mouse model 
 
4.1 Introduction 
After establishing that iron oxide-loaded scaffolds can be used to non-invasively kill 
infiltrated cells under an alternating magnetic field (AMF) in vivo, additional questions 
need to be answered to determine if this approach could be therapeutically applied to 
ovarian cancer. In this chapter, studies were conducted to investigate whether our 
previously developed PCL-only and iron oxide-loaded scaffolds could capture 
disseminated ovarian cancer cells in vivo in an advanced stage ovarian cancer mouse 
model. We also sought to identify when cancer cells would be evident at the scaffolds 
during disease progression and where the cancer cells would be located (i.e. within scaffold 
pores or on the outside). By better understanding these conditions, future therapeutic 
studies can be designed so that the therapeutic benefit of iron oxide-loaded scaffolds under 
AMF can be maximized, and non-invasive hyperthermic treatment of disseminated ovarian 
cancer cells can be investigated as a novel alternative treatment modality for advanced 
stage ovarian cancer. 
 
As indicated above, any new technology or treatment must first be investigated in in vivo 
models before it can be translated to the clinic. Ovarian cancer mouse models consist of 
patient derived-xenograft (PDX) models, models established using in vitro human tumor 
cell lines, and syngeneic models. In ovarian cancer, PDX models are established from 
patient primary tumor tissue or tumor cells from ascites. PDX models allow for patient-
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specific study of a tumor’s response to various treatments, but this type of model requires 
a lot of time to graft the patient material into mice and to expand the colonies of mice which 
have successfully established tumors. Additionally, because human material is being 
grafted into mice, immunodeficient mice (which are genetically modified to lack certain 
immune cell populations) are required for use. In ovarian cancer, three commonly used 
immunodeficient mouse strains are nude mice (T cell deficient), severe combined 
immunodeficient (SCID) mice (T cell and B cell deficient), and NOD SCID gamma (NSG) 
mice (B cell, T cell, and NK cell deficient, hemolytic complement deficient, and have 
defective macrophages and dendritic cells)188,189. Similarly, ovarian cancer mouse models 
established from in vitro human tumor cell lines, like SKOV-3 and IGROV-1, also require 
immunodeficient mice. Because immunodeficient mice lack immune system components, 
“humanized mouse models” - where not only human tumor cells are injected but also 
human hematopoietic stem cells for later differentiation in vivo - have been 
developed188,190. Although this type of model allows for immunotherapy studies, some cell 
lineages are never developed (i.e. erythrocytes, neutrophils190) or only differentiate to an 
immature state (i.e. T and B cells191).  
 
Contrastingly, syngeneic mouse models are established from allografts of mouse tumor 
cell lines into mice of the same genetic strain, and consequently, these mouse models have 
fully intact immune systems. The ID8 murine ovarian cancer cell line is the most widely 
used cell line for syngeneic ovarian cancer mouse models. The ID8 cell line was developed 
through serial passaging of C57/BL6 mouse ovarian surface epithelial cells167, and they 
exhibited an altered morphology and loss of contact-inhibited growth. Further, the 
tumorigenicity of these cells was verified after their subcutaneous and intraperitoneal (i.p.) 
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injection into C57/BL6 mice resulted in tumor formation. Since its creation, the ID8 mouse 
model has been extensively used in therapeutic studies investigating drug treatments and 
immunotherapy applications due to the model having a fully intact immune system. 
Because our ultimate goal is to determine whether iron oxide-loaded scaffolds can kill 
ovarian cancer cells under AMF and potentially elicit an antitumor immune response, use 
of the syngeneic ID8 ovarian cancer mouse model in these studies is desired.   
 
As mentioned previously, polymer scaffolds have been shown to localize disseminated 
ovarian cancer cells in vivo in a mouse model75. However, these findings were 
demonstrated in a model using the human SKOV-3 ovarian cancer cell line and 
immunodeficient SCID Beige mice, and even the authors acknowledged that a “limitation 
is that these preclinical studies have been conducted in immuno[deficient] mice.” Although 
a therapeutic benefit was observed when these scaffolds were implanted and then later 
removed after disease localization, the design of our iron oxide-loaded scaffolds improves 
upon this by allowing for repeated non-invasive heating and killing of cancer cells under 
AMF and would not require surgical removal to lower the disease burden. Iron 
oxide/gelatin composite scaffolds functionalized with folic acid for enhanced cancer cell 
recognition have previously been used to heat and kill HeLa cervical cancer cells in vitro179, 
but their ability to successfully capture cancer cells in an in vivo model was never 
examined. Lastly, our group has demonstrated the utility of microporous PCL scaffolds to 
recruit and kill metastatic cancer cells in a breast cancer mouse model76,77,85, but the 





In this chapter, we investigated whether our PCL-only and iron oxide-loaded scaffolds can 
capture disseminated ovarian cancer cells in vivo. Disseminated ovarian cancer cells were 
successfully captured using both types of scaffolds in an advanced stage ID8 ovarian cancer 
mouse model. The ID8 mouse model exhibited hallmarks of advanced patient disease, 
including ascites formation and peritoneal metastases. Because the ID8 cell line was not 
labeled with a fluorescent or bioluminescent marker, a method to quantify the disease state 
through necropsy evaluation was developed for tracking disease progression and 
comparing experimental groups in future studies. PCL-only scaffolds captured ID8 cells 
regardless of whether they were implanted before or during disease formation. Lastly, iron 
oxide-loaded scaffolds captured ID8 cells before extensive disease formation, allowing for 
potential hyperthermic treatment prior to significant disease burden in future therapeutic 
studies.  
 
4.2 Materials and Methods 
4.2.1 ID8 ovarian cancer mouse model 
All animal studies were approved and conducted following the guidelines under the 
University of Minnesota’s Institutional Animal Care and Use Committee. As mentioned in 
Chapter 3.2.4, mouse ID8 ovarian cancer cells were kindly gifted from Dr. Katherine Roby 
and were cultured as previously described. To establish an advanced stage ovarian cancer 
mouse model, 10 million ID8 cells in 400 μL phosphate buffered saline (PBS) were 
injected i.p. with a 25.5 gauge needle (0.0143 inch nominal inner diameter to minimize cell 
shearing) into female C57/BL6J mice (Jackson Laboratory). The weight and abdomen size 
(length and width) of each mouse were measured immediately prior to ID8 cell injection 
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and measured periodically throughout disease progression using a scale and digital 
calipers, respectively. For studies monitoring disease progression to end-stage disease, a 
disease end-point metric of a 30 gram (g) weight and visual abdominal swelling was used, 
and mice were humanely euthanized at this point of significant disease burden.  
 
4.2.2 Scaffold fabrication and implantation 
PCL-only and iron oxide-loaded scaffolds were fabricated as previously described in 
Chapter 3.2.1. For these studies, PCL-only scaffolds were created from 3 mg PCL 
microspheres and 90 mg sieved salt (250 - 425 µm), while iron oxide-loaded scaffolds were 
created from 3 mg PCL microspheres, 90 mg sieved salt (250 - 425 µm), and 2 mg of iron 
oxide bulk powder (spherical, < 44 μm Fe3O4 particles, Lansco 8330M). Surgical 
implantation of scaffolds into the i.p. cavity was also completed in the same manner as 
previously described in Chapter 3.2.7. In studies investigating capture of ID8 cells by PCL-
only scaffolds, one PCL-only scaffold was implanted per mouse and placed on the left side 
of the midline incision next to the i.p. wall. The final study investigating capture of ID8 
cells by iron oxide-loaded scaffolds involved implantation of two iron oxide-loaded 
scaffolds in the i.p. cavity of each mouse, with a scaffold on each side of the midline 
incision next to the i.p. wall. 
 
4.2.3 Necropsy evaluation 
Weight and abdominal measurements were taken prior to necropsy evaluation as described 
above. Glucose levels were measured by sampling blood from the tail vein using a 
glucometer (Contour Next EZ, Bayer). At study end-points, all ascites fluid was carefully 
removed from the intact abdominal cavity using a needle and syringe, and the total volume 
removed was recorded. After removal of ascites fluid, the abdominal cavity was opened, 
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and digital calipers were used to measure metastatic nodules on the i.p. wall. Visual disease 
scoring was done consistently by the same individual, and scores for individual 
organs/tissues and an overall score were given following the criteria shown below in Table 
4.1 and Table 4.2, respectively.  
 
Table 4.1: Criteria adapted from Roby et al. used for visual disease scoring of individual organs 
and tissues during necropsy evaluation167. 
Score Criteria 
0 No metastases evident by visual examination 
1 Metastases visually evident in an isolated area of tissue/organ 
2 Moderate formation of metastases in multiple areas of tissue/organ  
3 Extensive metastases on majority of tissue/organ  
 







4.2.4 Histological analysis 
Processing, slicing, and hematoxylin and eosin (H&E) staining were completed for 
harvested scaffolds as described previously in Chapter 3.2.8. Briefly, harvested scaffolds 
were immediately placed in 10% buffered formalin solution (Millipore Sigma) then later 
transferred to 70% ethanol prior to being embedded in paraffin blocks. 4 µm sections were 
obtained using a HM 315 microtome (Microm) then stained with H&E dyes. Stained 
scaffold sections were imaged using an EVOS FL Auto Microscope (Thermo Fisher 
Scientific). 
Score Criteria 
0 No metastases evident by visual examination 
1 One tissue/organ with metastases 
2 Moderate metastases on more than one tissue/organ 




4.3.1 ID8 ovarian cancer mouse model exhibits hallmarks of advanced patient disease 
To investigate whether iron oxide-loaded scaffolds under AMF can be used as a novel 
treatment modality for ovarian cancer, an advanced stage ovarian cancer mouse model 
representative of patient disease is needed. In initial studies, ID8 cell number and needle 
size used for i.p. injection of cells into female mice were optimized, and 10 million ID8 
cells resulted in significant disease formation. Control mice which received no ID8 cells 
maintained a normal body type throughout the study (Fig. 4.1A), while mice which 
received ID8 cells eventually exhibited visual abdominal swelling (Fig. 4.1B) due to 
significant production and accumulation of ascites fluid (Fig. 4.1C), which is consistent 
with what is observed in patients in the clinic. Further, metastases were evident throughout 
the peritoneal cavity of the mice, and metastatic nodules could be clearly seen on the i.p. 
lining or as clusters on abdominal organs and tissues (Fig. 4.1D&E). A disease end-point 
metric of 30 g weight and visual abdominal swelling for significant disease burden was 







Figure 4.1: ID8 ovarian cancer mouse model exhibits hallmarks of advanced patient disease.               
(A) Example of control mouse with no ID8 cell injection. (B,C) Images of ID8 mouse with 
advanced disease as seen by clear abdominal swelling (B) due to significant accumulation of ascites 
fluid (C). (D,E) Macrometastases are visible on organs and tissues in the abdominal cavity (dashed 
circles) and are also present as metastatic nodules on the i.p. wall (arrow, E). 
 
Using histology, the i.p. lining of control mice and ID8-injected mice was also compared. 
H&E staining of sections of i.p. lining showed a smooth surface with a thin layer of cells 
in control mice (Fig. 4.2A). In ID8-injected mice, micrometastases presenting as large 
clusters of cells attached to the i.p. lining were observed by histology (Fig. 4.2B), in 
addition to the larger macrometastatic nodules visible by eye. Metastatic nodules exhibited 
densely packed nuclei along with evidence of blood vessel formation (Fig. 4.2C). Overall, 
the i.p. injection of the ID8 cell line was verified to establish an advanced stage ovarian 
cancer mouse model that exhibits hallmarks of advanced patient disease, such as ascites 





Figure 4.2: Histology of tissues from naïve and ID8 mice. Images of H&E staining of i.p. lining 
from a control mouse (no ID8 cells injected, A), i.p. lining from an ID8 mouse (B), and ID8 
metastatic nodule (C). Scale bar indicates 200 μm. 
 
4.3.2 PCL-only scaffolds implanted during disease progression capture disseminated ID8 
cells  
The next study evaluated whether PCL-only scaffolds could capture disseminated ID8 cells 
in vivo. Ten million ID8 cells were injected i.p. into female mice, and PCL-only scaffolds 
were implanted into mice next to the i.p. wall 9 weeks into disease progression and later 
harvested for histology (Fig. 4.3A). This experimental scheme where scaffolds are 
implanted after ID8 cell injection would be representative of a clinical situation where 
patients have remaining disease after initial treatment or exhibit recurrence, and a scaffold 
is implanted to capture disseminated cells. A group of ID8 mice which did not receive 
scaffolds (“ID8”) was used to compare disease progression, and a group of naïve mice (no 
ID8 cell injection) that received PCL-only scaffolds was used as a control (“PCL-only”). 
After ID8 cell injection, the weight and abdomen size of the mice were monitored over 
time (Fig. 4.3B&C). Mice receiving ID8 cells exhibited a sharp increase in these two 
parameters around 90 days post-ID8 injection due to onset of ascites accumulation, while 
control mice with scaffolds only maintained a steady increase in weight and abdomen size. 
When ID8 mice reached the end-point of the study, the weight (30.8 ± 4.0 g and 31.0 ± 4.7 
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g for ID8 and ID8+PCL, respectively) and abdomen size (1060 ± 220 mm2 and 1080 ± 310 
mm2 for ID8 and ID8+PCL, respectively) of these mice were similar whether or not mice 
received PCL-only scaffolds (Fig. 4.3D&E). Control mice had an average weight of 25 ± 
0 g and an abdomen size of 570 ± 30 mm2. Lastly, the pancreas was observed to be 
significantly infiltrated with metastases in ID8 mice, so blood glucose level was compared 
across experimental groups to evaluate whether it could be used as a metric for monitoring 
disease progression. However, across all groups - including naïve mice - glucose levels 
were not found to be significantly different (Fig. 4.3F). 
  
Figure 4.3: Study of PCL-only scaffolds implanted during disease progression. (A) Timeline 
for ID8 ovarian cancer mouse study where PCL-only scaffolds were implanted after ID8 cell 
injection. (B,C) Comparison of weight (B) and abdomen size (length×width, C) over time after 
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ID8 cell injection across different experimental groups. (D-F) Average values for weight (D), 
abdomen size (E), and glucose level (F) at the 30 g weight and visual abdominal swelling disease 
end-point. *indicates P-value < 0.05 relative to “PCL” control group. 
 
Further, at disease end-point, mice receiving ID8 cells had a significant amount of ascites 
fluid (11.3 ± 4.6 mL and 12.2 ± 5.2 mL for ID8 and ID8+PCL, respectively, Fig. 4.4A). 
The maximum nodule size on the i.p. lining was found to be larger on average - although 
not statistically significant - in ID8 mice that did not receive PCL-only scaffolds than in 
ID8 mice with PCL-only scaffolds implanted at 9 weeks (Fig. 4.4B). Additional 
characterization of the disease state in the ID8 model at the end of this study was done 
through disease scoring of various tissues and organs in the abdominal cavity (Fig. 4.4C). 
In most ID8 mice with or without PCL-only scaffolds, the i.p. lining and pancreas were 
assigned a disease score of ~3 (2.9 ± 0.3 and 3 ± 0 for i.p. lining of ID8 and ID8+PCL, 
respectively, while both groups have a pancreas score of 3 ± 0), where extensive metastases 
are visible throughout. The liver was observed to have lower disease burden (disease scores 
of 1.8 ± 0.4 and 1.7 ± 0.5 for ID8 and ID8+PCL, respectively), where most mice had 
moderate metastases in multiple areas of the liver. Overall, extensive metastases were 




Figure 4.4: PCL-only scaffolds implanted during disease progression capture ID8 cells.     
(A,B) Amount of ascites fluid (A) and maximum i.p. nodule size (B) in ID8 mice without (“ID8”) 
or with PCL-only scaffolds (“ID8+PCL”) at the 30 g weight and abdominal swelling disease end-
point. PCL-only scaffolds were implanted at 9 weeks post-ID8 injection. (C) Extent of disease by 
visual scoring of the i.p. lining, liver, pancreas, and all organs/tissues (“overall”) at the disease end-
point. (D) H&E staining of a PCL-only scaffold that was found floating in ascites fluid in the 
abdominal cavity. (E) H&E staining of a PCL-only scaffold that was found attached to the i.p. wall. 
Scale bar indicates 200 μm. 
 
When PCL-only scaffolds were harvested for histology, it was observed through H&E 
staining that most scaffolds had captured ID8 cells on the border of the scaffold with 
evidence of nodules forming (Fig. 4.4D). Cell infiltration into the scaffolds was observed 
to a lesser extent, which is likely due to the late implantation of the PCL-only scaffolds (9 
weeks post-ID8 injection). At this time-point, some mice had ascites fluid during scaffold 
implantation, and significant ascites accumulation would occur soon after, likely hindering 
the ability of scaffolds to become embedded in the i.p. wall and to readily capture 
disseminated cells. This is supported by the fact that most scaffolds were found floating in 
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the ascites fluid. One scaffold which was found to be embedded in the i.p. wall exhibited 
enhanced cell infiltration along with formation of nodules on the border of the scaffold 
(Fig. 4.4E).  These findings demonstrate PCL-only scaffolds can capture disseminated ID8 
cells, although they should be implanted earlier in disease progression or attached to the 
i.p. wall for enhanced integration. Additionally, a method to quantitatively characterize the 
end-stage disease state of the ID8 mouse model was implemented, and it can be used in 
experiments investigating earlier time-points in disease progression or when studying the 
therapeutic benefit of scaffold-based interventions. 
 
4.3.3 PCL-only scaffolds implanted prior to disease formation capture disseminated ID8 
cells 
Conversely, an experimental scheme where PCL-only scaffolds were implanted prior to 
ID8 cell injection was investigated to similarly characterize how disease progresses in this 
case and whether PCL-only scaffolds could capture ID8 cells. A clinical scenario for this 
scheme would be when patients who are known to be at a higher risk of developing ovarian 
cancer - due to hereditary mutations (i.e. BRCA1, BRCA2)3,192 - may receive scaffolds 
prior to disease formation. Most mice received PCL-only scaffolds while a group of mice 
received mock surgeries, and 10 weeks later, 10 million ID8 cells were injected i.p. into 
mice (Fig. 4.5A). Again, control naïve mice receiving PCL-only scaffolds but not ID8 cells 
were used. A sharp increase in the weight and abdomen size was observed around 90 days 
post-ID8 injection (Fig. 4.5B&C), which is consistent with the previous study. Similarly, 
the weight of mice receiving ID8 cells (Fig. 4.5D, 31.0 ±1.4 g and 30.7 ± 2.4 g for ID8 and 
ID8+PCL, respectively) and their abdomen size (Fig. 4.5E, 910 ± 160 mm2 and 950 ± 200 
mm2 for ID8 and ID8+PCL, respectively) were not significantly different whether or not 
91 
 
mice received PCL-only scaffolds beforehand. The weight of PCL-only mice was lower at 
25 ± 0 g and the abdomen size was on average 640 ± 20 mm2 at the end of the study. 
Glucose levels were also comparable across groups and consistent with the levels of all 
mice in the previous study (Fig. 4.5F).  
 
Figure 4.5: Study of PCL-only scaffolds implantated prior to disease formation. (A) Timeline 
for ID8 ovarian cancer mouse study with implantation of PCL-only scaffolds before ID8 cell 
injection. (B,C) Comparison of weight (B) and abdomen size (length×width, C) over time 
following ID8 cell injection across different experimental groups. (D-F) Average values for weight 
(D), abdomen size (E), and glucose level (F) at the 30 g weight and visual abdominal swelling 
disease end-point. 
 
When comparing only the mice which received ID8 cells, the amount of ascites fluid (Fig. 
4.6A, 8.3 ± 2.4 mL and 7.0 ± 5.4 mL for ID8 and ID8+PCL, respectively) and maximum 
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i.p. nodule size (Fig. 4.6B, 3.8 ± 1.2 mm and 2.0 ± 0.8 mm for ID8 and ID8+PCL, 
respectively) were similar whether or not mice had PCL-only scaffolds. Lastly, average 
disease scores again showed extensive metastases on the pancreas (3 ± 0 and 2.6 ± 0.5 for 
ID8 and ID8+PCL, respectively) and i.p. lining (2.3 ± 0.8 and 2.6 ± 0.7 for ID8 and 
ID8+PCL, respectively), while the liver exhibited moderate disease burden (1.1 ± 0.4 and 
0.9 ± 0.4 for ID8 and ID8+PCL, respectively) (Fig. 4.6C).  
 
Figure 4.6: PCL-only scaffolds implanted prior to disease formation capture ID8 cells.      
(A,B) Amount of ascites fluid (A) and maximum i.p. nodule size (B) in ID8 mice without (“ID8”) 
or with PCL-only scaffolds (“ID8+PCL”) at the 30 g weight and abdominal swelling disease end-
point. PCL-only scaffolds were implanted 10 weeks prior to ID8 injection. (C) Extent of disease 
by visual scoring of the i.p. lining, liver, pancreas, and all organs/tissues (“overall”) at end-stage 
disease. (D,E) H&E staining of PCL-only scaffolds showing evidence of infiltration with protein 
and cells, as well as evidence of vessel formation (arrow, D) and fat deposits (dashed circle, E). 
Scale bar indicates 200 μm. 
 
The PCL-only scaffolds in this study were mostly found embedded in the i.p. wall or in fat 
near the incision site, and consequently, these scaffolds were more infiltrated with 
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extracellular matrix and cells (Fig. 4.6D&E). Like before, a substantial layer of cells and 
evidence of metastatic nodule growth on the border of scaffolds was seen (Fig. 4.7), along 
with blood vessel formation in some scaffolds (Fig. 4.6D). Fat deposits within the scaffold 
pores were also observed which is consistent with where they were found during harvest 
(Fig. 4.6E). Overall, these two studies where PCL-only scaffolds were implanted into the 
abdominal cavity of advanced stage ovarian cancer mice demonstrate that PCL-only 
scaffolds can capture disseminated ID8 cells in vivo, regardless of whether scaffolds are 
implanted before or during disease formation. 
 
 
Figure 4.7: Cross-sectional view of PCL-only scaffold with captured ID8 cells. Two 10x 
magnification images combined to provide a full cross-sectional view of a H&E-stained PCL-only 
scaffold that was implanted for 10 weeks prior to ID8 cell injection. Scale bar indicates 400 μm. 
 
4.3.4 Iron oxide-loaded scaffolds become infiltrated with ID8 cells throughout disease 
progression 
Lastly, we wanted to 1) verify iron oxide-loaded scaffolds could capture disseminated ID8 
cells in vivo and 2) identify how early in disease progression these cells would be evident 
at the scaffold to inform the design of future therapeutic studies using iron oxide-loaded 
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scaffolds under AMF. All mice received 10 million ID8 cells i.p., and 4.5 weeks later, 2 
iron oxide-loaded scaffolds were implanted into the i.p. cavity of each mouse (Fig. 
4.8A&B). This timeline was chosen since the primary therapeutic application of iron 
oxide-loaded scaffolds would be when patients have residual disease after debulking 
surgery or in early stages of recurrence after unsuccessful chemotherapy. At 8.5, 10.5, and 
11.5 weeks post-ID8 injection, necropsy evaluation was completed and iron oxide-loaded 
scaffolds were harvested to characterize disease progression and ID8 cell infiltration of 




Figure 4.8: Study of iron oxide-loaded scaffolds implanted 4.5 weeks post-ID8 injection then 
harvested at various timepoints during disease progression. (A) Timeline for ID8 ovarian 
cancer mouse study in which 2 iron oxide-loaded scaffolds were implanted 4.5 weeks after ID8 cell 
injection, and scaffolds were harvested at various timepoints during disease progression. (B) Image 
of mouse during necropsy evaluation and location of iron oxide-loaded scaffolds (arrows) in the 
abdominal cavity. (C-E) Comparison of average weight (C), abdomen size (length×width, D), and 
glucose level (E) at various timepoints during disease progression (weeks post-ID8 injection). 
(F,G) Amount of ascites fluid (F) and maximum i.p. nodule size (G) observed during necropsy 
evaluation at various timepoints during disease progression. Fractions in (F) indicate portion of 
mice with ascites in each group. (H) The extent of disease by visual scoring of the i.p. lining, liver, 
pancreas, and all organs/tissues (“overall”). *indicates P-value < 0.05 between indicated groups. 
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Because necropsy evaluation occurred at multiple time-points during disease progression, 
the weight and abdomen size increased over time (Fig. 4.8C&D). Glucose levels for each 
group were also measured (Fig. 4.8E), and although the glucose level at 10.5 weeks post-
ID8 injection was significantly higher than at 8.5 weeks post-ID8 injection, further studies 
would need to be done to ensure this finding is consistent. Overall, the glucose levels in 
this study were similar to previous values in the PCL-only scaffold studies. 
 
The amount of ascites fluid and maximum i.p. nodule size also increased over time (Fig. 
4.8F&G). Although the difference in average ascites fluid amount was not statistically 
significant across time-points, it is important to note that only one mouse at 8.5 weeks and 
10.5 weeks post-ID8 injection had ascites fluid (0.5 mL and 1 mL, respectively), while all 
mice at 11.5 weeks post-ID8 injection had notable ascites accumulation (0.5 to 7 mL) (Fig. 
4.8F). Disease scores of organs and tissues in the abdominal cavity also increased over 
time (Fig. 4.8H). At 8.5 weeks post-ID8 injection, a disease score of 1 was given to all 
mice for the i.p. lining (indicating some metastatic nodules isolated to a single region), 
while most mice in this group had no visual metastases on the liver or the pancreas. 
However, just 2 weeks later, mice were observed to have moderate metastases formation 
on the i.p. lining and pancreas, with 10 - 20% of the pancreas having visible disease. By 
11.5 weeks post-ID8 injection, most mice have extensive metastases across the i.p. lining 
and pancreas (80% covered) and moderate to extensive metastases on the liver. These 
findings indicate that future therapeutic studies investigating hyperthermic treatment of 
iron oxide-loaded scaffolds under AMF should utilize hyperthermic treatment prior to 11.5 
weeks post-ID8 injection before the disease burden is too high. Additionally, the 
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quantitative method which was developed to characterize the disease state of the ID8 model 
was further validated and was shown to be indicative of disease progression over time. 
 
Figure 4.9: Iron oxide-loaded scaffolds capture ID8 cells throughout disease progression. 
Images of H&E staining of an iron oxide-loaded scaffold with presence of blood from ascites fluid 
(dashed circles) within pores at 8.5 weeks post-ID8 injection (A) and iron oxide-loaded scaffolds 
harvested at 8.5 weeks (B), 10.5 weeks (C), and 11.5 weeks (D) post-ID8 injection. Nodules and 
tumor cell clusters can be seen on the edges of the scaffolds (arrows, B & C) and cancer cells are 
observed within all scaffolds as clusters of large, misshapen nuclei (dashed circles, B-D). Black 
material in images is iron oxide left behind after processing and staining. Scale bar indicates 200 
μm. 
 
Lastly, H&E staining of iron oxide-loaded scaffold sections was completed to characterize 
the infiltration and capture of ID8 cells over time. Evidence of ascites (red blood cells, 
dashed circles) within scaffold pores was observed in some iron oxide-loaded scaffolds 
(Fig. 4.9A). Importantly, even at the earliest evaluated time-point of 8.5 weeks post-ID8 
injection, clusters of large, misshapen nuclei (dashed circles) were seen throughout the iron 
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oxide-loaded scaffolds, indicating successful infiltration of ID8 cancer cells (Fig. 4.9B). 
Further, evidence of nodule formation on the border of iron oxide-loaded scaffolds (arrow) 
is seen even at this stage of disease. Consequently, at later time-points of 10.5 and 11.5 
weeks post-ID8 injection, these clusters of ID8 cells (dashed circles) are even larger and 
can fill almost the entirety of iron oxide-loaded scaffold pores (Fig. 4.9C&D). Again, large 
nodules appear to be forming on the scaffold border (arrow, Fig. 4.9C). Overall, these 
findings show that iron oxide-loaded scaffolds can successfully capture disseminated ID8 
cells in vivo (both within and on the outside of scaffolds), and more importantly, ID8 cells 
are observed at the iron oxide-loaded scaffolds prior to significant disease formation.  
 
4.4 Discussion 
Due to the lack of treatment options for advanced stage ovarian cancer patients, this chapter 
focused on further investigating whether our previously developed PCL-only and iron-
oxide loaded scaffolds could be used as an alternative treatment modality for disseminated 
disease. More specifically, the potential of these scaffolds to capture disseminated cancer 
cells in vivo in an advanced stage ovarian cancer mouse model was investigated. First, 
tumor inoculation was optimized in order to successfully implement this model, which was 
new to our group, and it was determined that ID8 cell number and the needle size used for 
i.p. injection of the cells were critical for successful establishment of metastatic disease in 
the model (data not shown). Because this work aims to help advanced stage ovarian cancer 
patients, the ID8 mouse model was verified to exhibit hallmarks of advanced patient 
disease, such as ascites accumulation and metastases throughout the abdominal cavity. In 
ID8 mice, significant accumulation of ascites fluid resulted in visual abdominal swelling 
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which was used as a metric for end-stage disease. This characteristic of the mouse model 
is clinically-relevant, as most ovarian cancer patients will present with advanced stage 
disease at time of diagnosis and some will already have ascites193. In ovarian cancer 
patients, a typical cellular distribution of 37% lymphocytes, 29% mesothelial cells, 32% 
macrophages, and less than 0.1% adenocarcinoma cells in ascites fluid has been 
reported194. The accumulation of ascites is due to a disrupted balance between fluid 
production and filtration in the peritoneal cavity195. Impaired fluid draining through 
lymphatics due to tumor cell obstruction has long been hypothesized as one of the main 
mechanisms for ascites accumulation196. Additionally, increased flow of fluid into the 
peritoneal cavity through enhanced microvessel permeability197 and multiple mechanisms 
due to enhanced vascular endothelial growth factor (VEGF) expression195 are suggested. 
 
Further, ID8 mice exhibited extensive metastases (both micrometastases visualized by 
microscopy and macrometastases visible by eye) on the tissues and organs of the abdominal 
cavity. As seen in the ID8 model, ovarian cancer patients typically have locally advanced 
disease confined within the peritoneal cavity, and spread of ovarian cancer cells from the 
primary tumor differs from other cancers which often metastasize through blood 
vasculature22. Shedding of ovarian cancer cells from the primary tumor and their 
subsequent transport via fluid throughout the peritoneal cavity is widely accepted as one 
of the main routes of passive metastasis in epithelial ovarian cancer22,198,199. Consequently, 
if no accumulated fluid is present, cancer cells would be restricted to dispersing at sites 
nearby the primary tumor200,201, demonstrating the significant role ascites fluid plays in 




Most notably, although disseminated ovarian cancer cells spread throughout the peritoneal 
cavity, the distribution of metastases is not completely random, and common sites of 
metastasis are the peritoneum and the omentum26. The peritoneum is the membrane lining 
the peritoneal cavity and abdominal organs, and ovarian cancer cells will adhere to its outer 
layer called the mesothelium, then upregulate matrix metalloproteinase-2 (MMP-2) to 
invade further into the cell layer22. Knowing that disseminated ovarian cancer cells are 
typically confined within the peritoneal cavity of patients and will spread to the 
peritoneum, the i.p. wall was chosen as the site of scaffold implantation to increase the 
capture of disseminated cancer cells.  
 
Another consideration with the ID8 mouse model used here is that since the tumor cells 
are injected i.p., this model is representative only of late stage disease where cancer cells 
are already in a disseminated state. I.p. injection of tumor cells is a standard method for 
establishing disease in ovarian cancer mouse models; however, an advanced stage ovarian 
cancer mouse model can be achieved through orthotopic injection of ID8 cells into the 
ovarian bursa of female mice, allowing primary tumors to grow first followed by metastatic 
spread202–204. An orthotopic model and natural progression to metastatic disease is indeed 
more representative of what will occur in patients, but the procedure to inject ID8 cells 
directly into the ovarian bursa is much more complex and requires surgery when compared 
to a simple i.p. injection. However, it may be advantageous to use an orthotopic ID8 mouse 
model in future studies to establish whether iron oxide-loaded scaffolds can capture 
disseminated ID8 cells even during the earliest stages of metastasis from a primary tumor.  
 
Regardless of whether or not PCL-only scaffolds were implanted, a sharp increase in 
weight and abdomen size began around 90 days post-ID8 injection in all ID8 mice. These 
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results were consistent with findings observed by Greenaway et al., where ID8 orthotopic 
tumors were first formed and by 90 days post-injection, significant peritoneal metastases 
and ascites fluid were present203. Further, the original work describing the creation of the 
ID8 cell line reports that the average time to death (determined by visual abdominal 
swelling) was 114 ± 3 days167 in mice, which is close to the time it took our ID8 mice to 
reach the disease end-point metric of 30 g and visual abdominal swelling (14 to 16 weeks). 
The consistency in disease progression across these studies and ours demonstrates the 
robustness of the disease timeline for the ID8 model. Although the disease timeline is 
consistent, the ID8 cells do not express a fluorescent or bioluminescent marker, which 
makes tracking the disease burden over time and comparing experimental groups more 
difficult. However, a quantitative method to characterize the disease state in the ID8 mouse 
model was developed through necropsy evaluation, and it will be used in future therapeutic 
studies to track disease progression after treatment (i.e. hyperthermic treatment with iron 
oxide-loaded scaffolds under AMF). 
 
The localization of ID8 cells within PCL-only scaffolds was also characterized. For the 
PCL-only scaffolds that were implanted during disease progression, most scaffolds were 
found floating in ascites with ID8 cells primarily seen on the scaffold border, while one 
scaffold that was found to be embedded in the i.p. wall had enhanced cell infiltration. 
Capture of ID8 cells primarily on the border is likely because the scaffolds were implanted 
too late into disease progression (9 weeks post-ID8 injection). Mice will begin to 
accumulate ascites fluid shortly after this time, and a couple of mice already had some 
ascites during scaffold implantation. Significant fluid accumulation and fluid flow would 
hinder the integration of scaffolds into the i.p. wall and consequent cell migration and 
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infiltration into scaffolds. Furthermore, previous studies showed PCL-only scaffolds 
implanted at this location in naïve mice exhibited cell infiltration. Additional studies where 
scaffolds are attached to the i.p. wall during implantation (i.e. using surgical glue) should 
be completed to determine if scaffolds can still become infiltrated with cells in the presence 
of ascites fluid. These studies would indicate whether scaffold integration into the i.p. wall 
is necessary for successful cell infiltration or if significant fluid in the peritoneal cavity 
alone would disrupt cell adherence and migration into scaffolds. If scaffolds cannot 
effectively capture ID8 cells when significant ascites fluid is present, scaffolds could be 
implanted earlier in disease progression prior to formation of ascites or ascites fluid could 
be periodically drained - which is routinely done in patients - after scaffold implantation.  
 
When PCL-only scaffolds were implanted prior to ID8 cell injection, most scaffolds were 
found to be embedded in the i.p. wall or in fat. All of these scaffolds exhibited tissue 
infiltration within the scaffold pores, in addition to evidence of metastatic nodule formation 
on the scaffold border. Scaffold embedment into fat in the peritoneal cavity and evidence 
of fat within scaffold pores are interesting since 80% of serous ovarian cancer patients will 
have metastases at the omentum205, a fat pad made up largely of adipocytes. Further, 
numerous studies have found evidence strongly suggesting adipocytes contribute to the 
homing, migration, and proliferation of metastatic ovarian cancer cells199,205, and the fat 
surrounding and within scaffolds could also be aiding in ID8 cell recruitment. These studies 
demonstrated that PCL-only scaffolds could capture disseminated cancer cells in an 
advanced stage ovarian cancer mouse model, whether the scaffolds were implanted before 
ID8 cell injection or during disease formation. These PCL-only scaffolds have previously 
been shown to capture metastatic cancer cells in a breast cancer mouse model76,77,85; 
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however, this is the first time they have been shown to capture disseminated ovarian cancer 
cells in vivo. 
 
In a final study, iron-oxide loaded scaffolds were investigated for their potential to capture 
ID8 cells in vivo. Iron oxide-loaded scaffolds were implanted earlier in disease progression 
(4.5 weeks post-ID8 injection) because this timeline is most clinically-relevant, as patients 
could receive iron oxide-loaded scaffolds to treat residual disease after debulking surgery 
or after detecting recurrence. Necropsy evaluation occurred at 8.5, 10.5, and 11.5 weeks 
post-ID8 injection, and trends of increasing values in weight, abdomen size, ascites fluid, 
maximum i.p. nodule size, and disease scores were observed over time which was expected 
due to disease progression. Interestingly, disseminated ID8 cells were observed at iron 
oxide-loaded scaffolds at all these time-points, and extensive disease formation was not 
necessary for ID8 cells to be captured, indicating AMF treatment could be given prior to 
significant disease burden. Because ID8 cells are captured at iron oxide-loaded scaffolds 
and we previously demonstrated that cells within iron oxide-loaded scaffolds can be killed 
non-invasively under AMF206, future in vivo studies investigating whether this modality 
can be used for a therapeutic benefit are warranted. As mentioned in Chapter 3, a larger 
coil is needed for this, so that the mouse and the entire implanted iron oxide-loaded scaffold 
can be uniformly treated under AMF in vivo. Although no significant differences were 
observed in the disease progression between ID8 mice that received PCL-only scaffolds 
and ID8 mice that did not, iron oxide-loaded scaffolds could slow disease progression by 
repeatedly heating and killing captured ID8 cancer cells to lower disease burden and by 
also potentially eliciting an antitumor immune response. To address ID8 cells observed on 
the scaffold border, a longer AMF treatment time could be used, where the surrounding 
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tissue around the iron oxide-loaded scaffold would reach appropriate temperatures for cell 
death85. Another option is to find earlier timepoints where a significant layer of cells do 
not form on the scaffold border, and treating at an earlier time in disease progression would 
be beneficial because a significant volume of ascites fluid in the peritoneal cavity at later 
stages of disease would affect the heating and heat transfer of iron oxide-loaded scaffolds. 
Future studies investigating whether ID8 cells are observed at iron oxide-loaded scaffolds 
prior to 8.5 weeks post-ID8 injection should be considered, as it is highly likely that ID8 
cells would be observed at these scaffolds earlier although in lesser numbers. Overall, this 
last finding that ID8 cells are captured by iron oxide-loaded scaffolds prompts future work 
investigating whether ID8 cells which are killed via hyperthermic treatment can elicit an 


















Chapter 5: Conclusions and future directions 
 
5.1 General conclusions 
The overall goal of this research was to improve ovarian cancer treatment through 
development of innovative biomaterial-based approaches which could help address the 
long-standing clinical challenges of recurrence, chemoresistance, and limited therapeutic 
options for advanced stage disease. In the first project, ovarian cancer cell response to 
immobilization in stiff silica gels was extensively characterized. While most immobilized 
cells die within days, it was discovered that a subset of ovarian cancer cells have enhanced 
survival under physical confinement by entering dormancy. These cells that survived 
immobilization could be extracted from gels and demonstrated enhanced survival upon re-
immobilization relative to the starting population, indicating that immobilization quickly 
identifies a unique subpopulation that can readily enter dormancy in order to tolerate 
physical confinement stress. These cells also exhibited enhanced resistance to cisplatin and 
paclitaxel, despite being proliferative during treatment. Other in vitro platforms which have 
been used to study quiescence were unable to effectively select for chemoresistant ovarian 
cancer cells upon lifting the environmental stress, demonstrating that the rapid selection of 
chemoresistant cells after stress removal is unique to the silica gel platform. Lastly, ovarian 
cancer cells which were more resistant to both types of chemotherapy had enhanced 
survival in silica gels relative to more chemosensitive cells.  
 
In the next project, iron oxide particles were incorporated into biomaterial scaffolds which 
have previously been shown to recruit metastatic breast cancer cells76,77,85. After successful 
incorporation of iron oxide into scaffolds, it was demonstrated that simple design 
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parameters, such as iron oxide loading amount and magnetic field strength, could be tuned 
to alter the heating of iron oxide-loaded scaffolds under an alternating magnetic field 
(AMF). Addition of iron oxide into scaffolds did not cause significant cytotoxicity, and 
ID8 ovarian cancer cells were effectively heated and killed in iron oxide-loaded scaffolds 
under AMF in vitro. These scaffolds were implanted into the abdominal cavity of female 
mice and became infiltrated with tissue after 6-7 weeks. When removed and placed in the 
center of a radiofrequency coil, tissue-laden iron oxide-loaded scaffolds effectively killed 
infiltrated cells ex vivo under AMF. It was lastly demonstrated that implanted iron oxide-
loaded scaffolds could be used to successfully kill infiltrated cells in vivo in a non-invasive 
manner under AMF. 
In final studies, an advanced stage ovarian cancer mouse model using the ID8 cell line was 
verified to exhibit hallmarks of advanced patient disease, including ascites accumulation 
and extensive metastases within the peritoneal cavity. A quantitative method using 
necropsy evaluation was implemented to characterize the disease state during disease 
progression and at the end-stage of disease. PCL-only scaffolds were able to capture 
disseminated ID8 cells in vivo in the advanced stage mouse model, regardless of whether 
they were implanted before ID8 injection or during disease progression. Most importantly, 
iron oxide-loaded scaffolds captured ID8 cells prior to significant disease formation, 
indicating that hyperthermic treatment of cancer cells could be administered prior to 
extensive disease burden. With this last finding and previous work showing iron oxide-
loaded scaffolds can kill infiltrated cells under AMF in vivo, future studies investigating 
whether this treatment modality can provide a therapeutic benefit are of significant interest.   
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5.2 Future directions 
5.2.1 Silica gel immobilization of patient ovarian cancer cells to predict patient outcome 
In Chapter 2, chemoresistant ovarian cancer cells demonstrated a differential response - as 
evidenced by enhanced survival - to physical confinement when compared to cells which 
were more chemosensitive. Similarly, ovarian cancer cells with enhanced ability to enter 
dormancy also showed enhanced survival upon immobilization. Because these ovarian 
cancer cell populations can lead to recurrence, studies should be done to investigate 
whether patient tumor cell survival within silica gels indicates whether or not patients may 
have these evasive types of cancer cells and are at high risk of recurrence.  
 
Figure 5.1: Schematic of silica gel immobilization of ovarian cancer patient cells to investigate 
whether patient tumor cell survival is indicative of a patient’s response to chemotherapy or risk of 
recurrence. 
 
In preliminary studies immobilizing cells from patient samples (Fig. 5.1), samples were 
obtained from the UMN Tissue Procurement Facility, and the Miltenyi Biotec Tumor 
Dissociation Kit protocol was used to isolate cells for encapsulation. The protocol utilizes 
enzymatic degradation to break down the extracellular matrix and other unwanted proteins 
comprising the tumor’s tissue structure, followed by homogenization of the sample using 
a dissociator and mesh filter to mechanically remove any remaining tissue fragments 
leaving a cell suspension. Steps including accutase treatment to aid in further singularizing 
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cells and use of red blood cell lysis buffer to remove red blood cells were added to this 
protocol. This protocol provides a suitable method for initial collection of cells from 
tumors; however, all cells present in the tissue sample – including stromal cells such as 
fibroblasts – will be collected.  
Since the existing protocol will collect most cell types from the tumor sample, an additional 
step separating the ovarian cancer cells from the other stromal cells is required. It was 
predicted that many of the undesired cells retrieved from patient tumor samples would be 
fibroblasts as they are one of the most abundant cell types in the tumor stroma207. Previous 
reports have shown that separation of fibroblasts from other cells in solution may be 
completed by taking advantage of the relatively fast adhesion rate of fibroblasts208, and 
fibroblasts have been successfully removed by using a short incubation period where 
fibroblasts will adhere quickly to the flask surface and ovarian cancer cells will be left in 
suspension209. In our preliminary studies, an incubation period of 30 minutes for selective 
adherence of fibroblasts was used, and this incubation time should be further validated or 
optimized for the condition where most fibroblasts have adhered to the surface while 
ovarian cancer cells remain in suspension. Fibroblast removal efficiency should be 
determined using appropriate cell markers such as cytokeratin-7/CA-125 and CD90210,211 
for ovarian cancer cells and fibroblasts, respectively. Cytokeratin-7 is characterized as an 
ovarian epithelial marker212, and CA-125 is used as a standard ovarian cancer marker by 
clinicians213,214.  
If this method utilizing a short incubation period for selective adherence of fibroblasts 
results in poor fibroblast removal, previously used methods including cold Trypsin/EDTA 
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washes, culture in low-serum media, or magnetic bead separation may be tested as well211. 
It is likely that some stromal cells will be encapsulated within silica gels since 100% 
removal would be extremely difficult, but ovarian cancer cells can be specifically stained 
for within silica gels (i.e. cytokeratin-7 and CA-125 used in our preliminary work). 
Immobilization of a small number of stromal cells may not greatly alter the results of 
ovarian cancer cell survival within silica gels, as previous work has shown that non-
cancerous cell types demonstrate a rapid drop in metabolic activity after 1 – 1.5 days within 
silica gels98. However, future experiments should be done to verify these cells will die off 
quickly. Overall, if the cell extraction efficiency from samples and/or viability is found to 
be too low prior to immobilization, alternative protocols for collecting cancer cells from 
ovarian cancer biopsy samples that have been successfully used by Strauss et al. or Pribyl 
et al. could be explored215,216. 
After immobilization of ovarian cancer cells in silica gels, cell survival should be evaluated 
over a one-week period as done in previous work (Fig. 5.2), and the patient’s response to 
chemotherapy quantified by duration of progression-free survival (PFS) and the duration 
until recurrence following completion of treatment should be monitored. If strong 
correlations between cell survival and rate of recurrence/PFS are found, silica gel 
immobilization may be promising as a method to predict which patients are likely to recur. 
Further, if initial studies with ovarian cancer cells from tumor samples appear promising, 
ovarian cancer cells collected from the ascites fluid of patients may be encapsulated for 
another set of studies. This could also be an alternative option if there is difficulty isolating 
enough viable ovarian cancer cells from primary tumor samples, as cancer cells can be 
isolated from ascites fluid with less difficulty209. Overall, if a statistically significant 
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difference in survival of immobilized cells is observed between patients who recur within 
six months of completing treatment (chemoresistant) and patients who do not, these results 
may indicate the potential use of silica gels as a method to quickly identify patients who 
are likely to recur or have a poor response to chemotherapy.    
 
Figure 5.2: Preliminary studies evaluating cell survival upon silica gel immobilization using cells 
from various patient samples (both benign and malignant samples). Viable immobilized cells were 
stained and imaged at Day 0 and 7 of immobilization. Multi-cellular clusters are shown in images 
but additional optimization has improved singularization of cells prior to immobilization. Scale bar 
indicates 400 μm. 
 
 
5.2.2 Mechanistic studies to probe findings of RNA sequencing data analysis 
Experiments investigating findings from RNA sequencing data analysis of immobilized, 
extracted, and cisplatin-treated ovarian cancer cells are of interest. These data provided 
insight on the transcriptome-level response of surviving ovarian cancer cells to being 
physically confined or to being treated with cisplatin. Identifying altered signaling 
pathways in these cells relative to control cells cultured in standard 2-D conditions may 
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explain how cells within silica gels are entering dormancy under immobilization stress. A 
potential mechanism that has been identified from the RNA sequencing data involves 
activation of interferon signaling pathways.  
 
Multiple analyses indicated altered interferon signaling in our samples. The fold change in 
gene expression of genes known to become activated during interferon signaling (IFIT1, 
IFIT2, OAS1, and MX1) were significantly upregulated in all samples relative to controls 
(data not shown). Further, “Type 1 Interferon Signaling Pathway” was an enriched term in 
gene ontology (GO) enrichment analysis of Day 1 and Day 3 immobilized samples, and 
“Interferon Signaling” was identified as the most activated top canonical pathway (by z-
score) for these samples using Ingenuity Pathway Analysis (IPA) (Fig. 5.3A). Also from 
IPA, the upstream regulators function - which identifies regulators that are most likely to 
have caused the differential gene expression exhibited by our samples - identified many 
different interferons as potential activators of the differential gene expression we observed 




Figure 5.3: In Ingenuity Pathway Analysis, differentially expressed genes of Day 1 and Day 3 
immobilization samples were used, and differentially expressed genes were defined as genes with 
abs(log2FC) > 1, P-value < 0.05, and FDR < 0.05. (A) Top canonical signaling pathways (by z-
score) shared between Day 1 and Day 3 samples identified by IPA, where the activation z-score 
indicates the level of predicted activation (orange) or inhibition (blue) of a pathway based upon the 
differential expression of the genes. (B) Top upstream regulators (by z-score) predicted to lead to 
the differential expression observed in Day 1 and Day 3 samples, where the activation z-score 
indicates the level of predicted activation (orange) or inhibition (blue) of a regulator based upon 
the differential expression of the genes.    
 
 
Further analysis of the RNA sequencing data showed that the fold change in gene 
expression for interferon-alpha (IFNA1), interferon-beta (IFNB1), and interferon-gamma 
(IFNG) was negligible, but the fold change in gene expression of the gene for interferon-
lambda (IFNL1) was increased relative to controls in all experimental groups. It was later 
verified with RT-qPCR that IFNL1, OAS1, and MX1 were significantly upregulated in Day 
1 and Day 3 samples relative to controls (data not shown). Using an ELISA, evidence of 
interferon-lambda present in the media from silica gels with OVCAR-3 cells immobilized 
for 3 days was observed, but it was present in very low amounts (data not shown). Future 
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studies investigating if soluble interferons are being secreted by immobilized cells and 
causing downstream signaling in an autocrine or paracrine manner would be interesting, 
since interferons have previously been implicated in cell cycle arrest in multiple types of 
cancer. In gastric carcinoma cells, interferon-alpha and -gamma suppressed growth in vitro 
by inducing cell cycle arrest217, and interferon-lambda-1 was shown to specifically induce 
arrest in the G1 phase109. Similarly, G1 phase cell cycle arrest without apoptosis induction 
was observed in renal cancer cells in vitro due to interferon-alpha activation of parts of the 
Jak-Stat pathway218. Induction of p21 - a cyclin dependent kinase inhibitor that promotes 
cell cycle arrest under cellular stress - and growth inhibition were observed in ovarian and 
colon cancer cell lines after treatment with interferon-gamma219 and type I interferons220, 
respectively. We also observed statistically significant upregulation of the CDKN1A gene 
(which codes for p21) in our immobilized samples relative to controls using RT-qPCR 
(data not shown). Overall, the RNA sequencing data has provided avenues for 
identification and exploration of genes and pathways altered in immobilized, extracted, and 
treated samples. Additional experiments could improve mechanistic understanding of how 
a subset of cells enter dormancy in silica gels while many will quickly undergo apoptosis 
instead.   
5.2.3 Applying silica gel immobilization to other types of cancer cell lines and 
chemotherapies  
Because silica gel immobilization rapidly distinguished ovarian cancer cells with enhanced 
chemoresistance and ability to enter dormancy, studies determining whether this 
phenomenon would also be seen when immobilizing other cancer cell lines are warranted. 
Using the same studies as described in Chapter 2, experiments immobilizing other cancer 
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cell types should be done to see if surviving cells exhibit enhanced chemoresistance or 
survival upon re-immobilization, despite being in a proliferative state. Cancer cell types 
where it is also common for a subset of patients to exhibit recurrence after initial treatment 
(i.e. breast cancer221, lymphoma222) would be of greatest interest. Furthermore, because 
extracted ovarian cancer cells exhibited enhanced chemoresistance to platinum- and 
taxane-based chemotherapeutics, other drug types could be screened in this platform. 
Treating extracted ovarian cancer cells with other types of chemotherapies would inform 
whether the selected cells from silica gel immobilization have enhanced resistance to 
specific types of drugs or if they may have innate mechanisms which grant them decreased 
susceptibility to chemotherapies, regardless of the drug mechanism of action. 
 
5.2.4 Identifying in vitro hyperthermia conditions for an enhanced antitumor immune 
response using iron oxide-loaded scaffolds under AMF  
In Chapter 3, iron oxide-loaded scaffolds were shown to effectively generate heat under 
AMF and could be used to kill ovarian cancer cells in vitro. Further, the overall temperature 
rise during a 15-minute treatment could be changed by altering simple design parameters, 
such as the amount of iron oxide loaded into scaffolds and the magnetic field strength. 
Additional studies generating ovarian cancer cell lysates using different temperatures and 
heating durations could be completed to identify which hyperthermia conditions lead to 
generation of an effective antitumor immune response in vitro. These studies are of interest 
because there is limited understanding of which temperatures and treatment durations are 
best for robust antitumor immunity145,223. Previous work has shown that a difference of just 
a few degrees in cancer cell heating can cause different immune responses224,225, but it is 




In addition to iron oxide loading amount and magnetic field strength, there are 
opportunities to tune the heating of these scaffolds by also investigating other parameters, 
such as magnetic field frequency and iron oxide particle size and morphology. As 
mentioned in Chapter 3, superparamagnetic iron oxide nanoparticles have been extensively 
characterized in heating studies under AMF and could be incorporated into scaffolds for 
faster heating rates and to reach higher temperatures. Ovarian cancer cell lysates could be 
generated from different heating conditions using iron oxide-loaded scaffolds under AMF, 
and these lysates could be investigated for the ability to elicit an antitumor immune 
response as measured by antigen-specific T cell proliferation or functionality. 
If significant differences in T cell behavior are observed, additional lysate characterization 
studies could be completed to further elucidate which mechanisms led to differences in T 
cell response. Characterizing the mode of cell death (apoptosis vs. necrosis) - which is 
known to cause differences in immune response226 - and comparing the amounts of 
immunomodulatory proteins known to be important in antitumor immunity (e.g. HSP70, 
HSP90)145 would be of interest. Further, dendritic cell uptake, processing, and presentation 
of antigen from different ovarian cancer lysates could be evaluated, and this would help 
determine if hyperthermia conditions influence the development of antitumor immunity 
via dendritic cells. Overall, potential findings from studies like these would help advance 
the field, because the intersection of focal therapies - including hyperthermia - and 




5.2.5 Evaluating in vivo therapeutic potential of iron oxide-loaded scaffolds under AMF in 
an advanced stage ovarian cancer mouse model 
In Chapter 4, it was verified that iron oxide-loaded scaffolds could capture disseminated 
ID8 cells in vivo prior to significant disease formation. This finding prompts studies 
investigating whether these captured ID8 cells can be successfully killed under AMF and 
whether hyperthermic treatment of ID8 cells can act as an in situ vaccination method to 
elicit an antitumor immune response and mitigate disease progression. We have already 
observed ID8 cells captured at the iron oxide-loaded scaffolds as early as 8.5 weeks post-
ID8 injection, but it is likely that ID8 cells are present before then and AMF treatment 
could be administered earlier. Similar to previous studies, histological analysis of iron 
oxide-loaded scaffolds three days after AMF-treatment would verify whether ID8 cells 
were successfully killed. After verifying ID8 cells can be killed at iron oxide-loaded 
scaffolds, it would be interesting to determine if ID8 cells re-infiltrate scaffolds after 
successful AMF treatment and whether hyperthermic treatment could be administered 
multiple times to repeatedly decrease the disease burden.  
Further studies should investigate how early AMF treatment is needed or if AMF treatment 
is needed multiple times for disease progression to be slowed, relative to ID8 mice with 
iron oxide-loaded scaffolds that do not receive AMF treatment and ID8 mice with no 
scaffolds. Mice weight and abdomen size could easily be monitored throughout the study 
for comparison, and necropsy evaluation and disease scoring could be used to identify 
whether AMF treatment decreased the extent of disease of ID8 mice at the study end-point. 
To investigate whether hyperthermic treatment of ID8 cells elicits an antitumor immune 
response in vivo, phenotyping of immune cells in the peritoneal cavity could be done. 
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Comparison of pro-tumor and antitumor immune cell populations in ID8 mice with iron 
oxide-loaded scaffolds before and after AMF treatment would be most interesting to see if 
hyperthermia results in a less immunosuppressive environment. Overall, the time to disease 
end-point (30 g weight and visual abdominal swelling) for each experimental group would 
indicate whether iron oxide-loaded scaffolds under AMF can be effectively used to slow 
disease progression and enhance survival. Synergistic treatments combining iron oxide-
loaded scaffolds with other immunotherapies (i.e. immune checkpoint inhibition) should 
also be considered also in the future, since our collaborative work has previously shown 
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